|
Document And Entity Information
|
12 Months Ended |
|---|---|
|
Dec. 31, 2012
|
|
| Document and Entity Information [Abstract] | |
| Entity Registrant Name | TEKMIRA PHARMACEUTICALS CORP |
| Document Type | 20-F |
| Current Fiscal Year End Date | --12-31 |
| Entity Common Stock, Shares Outstanding | 14,305,356 |
| Amendment Flag | false |
| Entity Central Index Key | 0001447028 |
| Entity Current Reporting Status | Yes |
| Entity Voluntary Filers | No |
| Entity Filer Category | Non-accelerated Filer |
| Entity Well-known Seasoned Issuer | No |
| Document Period End Date | Dec. 31, 2012 |
| Document Fiscal Year Focus | 2012 |
| Document Fiscal Period Focus | FY |
| X | ||||||||||
|
- Definition
If the value is true, then the document is an amendment to previously-filed/accepted document. No definition available.
|
| X | ||||||||||
|
- Definition
End date of current fiscal year in the format --MM-DD. No definition available.
|
| X | ||||||||||
|
- Definition
This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY. No definition available.
|
| X | ||||||||||
|
- Definition
This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. No definition available.
|
| X | ||||||||||
|
- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD. No definition available.
|
| X | ||||||||||
|
- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other". No definition available.
|
| X | ||||||||||
|
- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. No definition available.
|
| X | ||||||||||
|
- Definition
Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. No definition available.
|
| X | ||||||||||
|
- Definition
Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. No definition available.
|
| X | ||||||||||
|
- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. No definition available.
|
| X | ||||||||||
|
- Definition
Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A. No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The cumulative amount of depreciation, depletion and amortization (related to property, plant and equipment, but not including land) that has been recognized in the income statement. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Total of all Liabilities and Stockholders' Equity items (or Partners' Capital, as applicable), including the portion of equity attributable to noncontrolling interests, if any. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Net amount of other deferred costs capitalized at the end of the reporting period. Does not include deferred finance costs or deferred acquisition costs of insurance companies. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The total of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer, and the aggregate carrying amount of current assets, as of the balance sheet date, not separately presented elsewhere in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Gross amount of long-lived physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount, net of accumulated depreciation, depletion and amortization, of long-lived physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The amount due for services rendered or products shipped, but not yet billed, recognized in conformity with revenue recognition criteria. This element is distinct from unbilled contracts receivables because this is based on noncontract transactions. No definition available.
|
| X | ||||||||||
|
- Definition
Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Consolidated Balance Sheets (Parentheticals) (CAD)
|
Dec. 31, 2012
|
Dec. 31, 2011
|
|---|---|---|
| Common shares, shares issued | 14,305,356 | 12,148,635 |
| Common shares, shares outstanding | 14,305,356 | 12,148,635 |
| Common shares, no par value (in Dollars per share) | ||
| Common shares, authorized |
| X | ||||||||||
|
- Definition
Issuance value per share of no-par value common stock; generally not indicative of the fair market value per share. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Other license revenue derived from amendments to contractual license agreements. No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Direct costs such as legal and accounting fees associated with issuing warrants. No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Revenue earned during the period arising from products sold or services provided under the terms of a contract, not elsewhere specified in the taxonomy. May include government contracts, construction contracts, and any other contract related to a particular project or product. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
For each line item in the statement of financial position, the amounts of gains and losses from fair value changes included in earnings. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The aggregate foreign currency transaction gain (loss) (both realized and unrealized) included in determining net income for the reporting period. Excludes foreign currency transactions designated as hedges of net investment in a foreign entity and intercompany foreign currency transactions that are of a long-term nature, when the entities to the transaction are consolidated, combined, or accounted for by the equity method in the reporting enterprise's financial statements. For certain enterprises, primarily banks, that are dealers in foreign exchange, foreign currency transaction gains (losses) may be disclosed as dealer gains (losses). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Income derived from investments in debt securities and on cash and cash equivalents the earnings of which reflect the time value of money or transactions in which the payments are for the use or forbearance of money. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. No definition available.
|
| X | ||||||||||
|
- Definition
The net result for the period of deducting operating expenses from operating revenues. No definition available.
|
| X | ||||||||||
|
- Definition
The amount of cash paid for the settlement of litigation or for other legal issues during the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Aggregate revenue recognized during the period (derived from goods sold, services rendered, insurance premiums, or other activities that constitute an entity's earning process). For financial services companies, also includes investment and interest income, and sales and trading gains. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Changes in additional paid in capital related to exercise of share-based payments awards (such as stock options) and the amount of recognized equity-based compensation during the period (such as nonvested shares). No definition available.
|
| X | ||||||||||
|
- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Number of new stock issued during the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Number of shares of stock issued during the period that is attributable to transactions involving issuance of stock not separately disclosed. No definition available.
|
| X | ||||||||||
|
- Definition
Number of share options (or share units) exercised during the current period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Value of shares of stock issued during the period that is attributable to transactions involving issuance of stock not separately disclosed. No definition available.
|
| X | ||||||||||
|
- Definition
Value of stock issued as a result of the exercise of stock options. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Condensed Consolidated Statement of Stockholders' Equity (Parentheticals) (CAD)
|
12 Months Ended | |
|---|---|---|
|
Dec. 31, 2012
|
Dec. 31, 2011
|
|
| Issuance of common shares, issuance costs | 178,407 | 475,568 |
| Issuance of common shares, initial fair value of warrants | 8,503,358 | 742,809 |
| X | ||||||||||
|
- Definition
Direct costs (e.g., legal and accounting fees) associated with issuing stock that is deducted from additional paid in capital. Also includes any direct costs associated with stock issues under a shelf registration. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Increase in additional paid in capital due to warrants issued during the period. Includes also the proceeds of debt securities issued with detachable stock purchase warrants that are allocable to the warrants. These warrants qualify for equity classification and provide the holder with a right to purchase stock from the entity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The effect of exchange rate changes on cash balances held in foreign currencies. No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The increase (decrease) during the reporting period in the amount of other deferred costs. Does not include deferred finance costs or deferred acquisition costs of insurance companies. No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Direct costs such as legal and accounting fees associated with issuing warrants. No definition available.
|
| X | ||||||||||
|
- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The effect of exchange rate changes on cash balances held in foreign currencies. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
For each line item in the statement of financial position, the amounts of gains and losses from fair value changes included in earnings. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The increase (decrease) during the reporting period of the amount of revenue for work performed for which billing has not occurred, net of uncollectible accounts. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The fair value of restricted stock or stock options granted to nonemployees as payment for services rendered or acknowledged claims. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The net cash inflow or outflow from financing activity for the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The net cash inflow or outflow from investing activity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The net cash from (used in) all of the entity's operating activities, including those of discontinued operations, of the reporting entity. Operating activities generally involve producing and delivering goods and providing services. Operating activity cash flows include transactions, adjustments, and changes in value that are not defined as investing or financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of cash received during the period as refunds for the overpayment of taxes. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The cash inflow from the additional capital contribution to the entity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The cash inflow associated with the amount received from holders exercising their stock warrants. No definition available.
|
| X | ||||||||||
|
- Definition
The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
|
Note 1 - Nature of business and future operations
|
12 Months Ended | ||
|---|---|---|---|
|
Dec. 31, 2012
|
|||
| Nature of Operations [Text Block] |
Tekmira
Pharmaceuticals Corporation (the “Company”) is a
Canadian biopharmaceutical business focused on advancing
novel RNA interference therapeutics and providing its leading
lipid nanoparticle delivery technology to pharmaceutical
partners.
The
success of the Company is dependent on obtaining the
necessary regulatory approvals to bring its products to
market and achieve profitable operations. The continuation of
the research and development activities and the
commercialization of its products are dependent on the
Company’s ability to successfully complete these
activities and to obtain adequate financing through a
combination of financing activities and operations. It is not
possible to predict either the outcome of future research and
development programs or the Company’s ability to fund
these programs in the future.
|
| X | ||||||||||
|
- Definition
The entire disclosure for the nature of an entity's business, the major products or services it sells or provides and its principal markets, including the locations of those markets. If the entity operates in more than one business, the disclosure also indicates the relative importance of its operations in each business and the basis for the determination (for example, assets, revenues, or earnings). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 2 - Significant accounting policies
|
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2012
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Significant Accounting Policies [Text Block] |
Basis
of presentation
Tekmira
Pharmaceuticals Corporation was incorporated on October 6,
2005 as an inactive wholly owned subsidiary of Inex
Pharmaceuticals Corporation
(“Inex”). Pursuant to a “Plan of
Arrangement” effective April 30, 2007 the business and
substantially all of the assets and liabilities of Inex were
transferred to the Company. The consolidated financial
statements for all periods presented herein include the
consolidated operations of Inex until April 30, 2007 and the
operations of the Company thereafter.
These
consolidated financial statements include the accounts of the
Company and its two wholly-owned subsidiaries, Protiva
Biotherapeutics Inc. and Protiva Biotherapeutics (USA), Inc.,
which were acquired on May 30, 2008. All intercompany
transactions and balances have been eliminated on
consolidation.
Use
of estimates
The preparation of
the consolidated financial statements in conformity with
generally accepted accounting principles requires management
to make estimates and assumptions about future events that
affect the reported amounts of assets, liabilities, revenue,
expenses, contingent assets and contingent liabilities as at
the end or during the reporting period. Actual
results could significantly differ from those
estimates. Significant areas requiring the use of
management estimates relate to recognition of revenue,
stock-based compensation, share purchase warrant valuation
and the amounts recorded as accrued
liabilities.
Cash
and cash equivalents
Cash
and cash equivalents are all highly liquid instruments with
an original maturity of three months or less when
purchased. Cash equivalents are recorded at cost
plus accrued interest. The carrying value of these cash
equivalents approximates their fair value.
Fair
value of financial instruments
We
measure certain financial instruments and other items at fair
value.
To
determine the fair value, we use the fair value hierarchy for
inputs used in measuring fair value that maximizes the use of
observable inputs and minimizes the use of unobservable
inputs by requiring that the most observable inputs be used
when available. Observable inputs are inputs market
participants would use to value an asset or liability and are
developed based on market data obtained from independent
sources. Unobservable inputs are inputs based on assumptions
about the factors market participants would use to value an
asset or liability. The three levels of inputs that may be
used to measure fair value are as follows:
Assets
and liabilities are classified based on the lowest level of
input that is significant to the fair value measurements.
Changes in the observability of valuation inputs may result
in a reclassification of levels for certain securities within
the fair value hierarchy.
The
Company’s financial instruments consist of cash and
cash equivalents, accounts receivable, investment tax credits
receivable, accounts payable and accrued liabilities,
warrants and promissory notes.
The
carrying values of cash and cash equivalents are recorded at
fair value based on quoted prices in active markets. The
carrying values of accounts receivable, investment tax
credits receivable and accounts payable and accrued
liabilities approximate their fair values due to the
immediate or short-term maturity of these financial
instruments.
As
quoted prices for the warrants are not readily available, the
Company has used a Black-Scholes pricing model, as described
in Notes 5 and 6, to estimate fair value. These are level 3
inputs as defined above.
The
following tables present information about the
Company’s assets and liabilities that are measured at
fair value on a recurring basis, and indicates the fair value
hierarchy of the valuation techniques used to determine such
fair value:
The
following table presents the changes in fair value of the
Company’s warrants:
Inventory
Inventory
includes materials assigned for the manufacture of products
for collaborative partners and manufacturing costs for
products awaiting acceptance by collaborative partners.
Inventory is carried at the lower of cost and net realizable
value. The cost of inventories includes all costs of
purchase, costs of manufacturing and other costs incurred in
bringing the inventories to their present location and
condition.
Materials
purchased for the Company’s own research and
development products, or, for collaborative partners where an
acceptance criteria does not apply, are not recorded as
inventory but are expensed at the time of receipt.
Property
and equipment
Property
and equipment is recorded at cost less impairment losses,
accumulated depreciation, related government grants and
investment tax credits. The Company records
depreciation using the straight-line method over the
estimated useful lives of the capital assets as
follows:
Leasehold
improvements are depreciated over their estimated useful
lives but in no case longer than the lease term, except where
lease renewal is reasonably assured. Assets held under
capital leases that do not allow for ownership to pass to the
Company are depreciated using the straight-line method over
their useful life, not exceeding the lease term.
Intangible
assets
The
costs incurred in establishing and maintaining patents for
intellectual property developed internally are expensed in
the period incurred.
Impairment
of long-lived assets
If
there is a major event indicating that the carrying value of
property and equipment may be impaired then management will
perform an impairment test and if the recoverable value,
based on undiscounted future cash flows, exceeds carrying
value then such assets are written down to their fair
values.
Revenue
recognition
The Company earns
revenue from research and development collaboration and
contract services, licensing fees and milestone
payments. Revenues associated with multiple element
arrangements are attributed to the various elements based on
their relative fair values or are recognized as a single unit
of accounting when relative fair values are not determinable.
Non-refundable payments received under collaborative research
and development agreements are recorded as revenue as
services are performed and related expenditures are
incurred. Non-refundable upfront license
fees from collaborative licensing and development
arrangements are recognized as the Company fulfills its
obligations related to the various elements within the
agreements, in accordance with the contractual arrangements
with third parties and the term over which the underlying
benefit is being conferred. Revenue earned under
contractual arrangements upon the occurrence of specified
milestones is recognized as the milestones are achieved and
collection is reasonably assured.
Revenue
earned under research and development manufacturing
collaborations where the Company bears some or all of the
risk of a product manufacturing failure is recognized when
the purchaser accepts the product and there are no remaining
rights of return.
Revenue
earned under research and development collaborations where
the Company does not bear any risk of product manufacturing
failure is recognized in the period the work is
performed.
Revenue
and expenses under the contract with the United States
Government are being recorded using the
percentage-of-completion method. Contract progress is based
on costs incurred to date. Expenses under the contract are
recorded in the Company’s consolidated statement of
operations and comprehensive income (loss) as they are
incurred. Government contract revenues related to expenses
incurred under the contract are recorded in the same period
as those expenses. Expenses accrued under the contract but
not yet invoiced are recorded in the Company’s balance
sheet as accrued liabilities and accrued revenues. Equipment
purchased under the contract is recorded on the
Company’s balance sheet as deferred expense and
deferred revenue and amortized, on a straight-line basis,
over the life of the contract.
Cash
or other compensation received in advance of meeting the
revenue recognition criteria is recorded on the balance sheet
as deferred revenue. Revenue meeting recognition criteria but
not yet received or receivable is recorded on the balance
sheet as accrued revenue.
Leases
and lease inducements
Leases
entered into are classified as either capital or operating
leases. Leases which substantially transfer all benefits and
risks of ownership of property to the Company are accounted
for as capital leases. At the time a capital lease
is entered into, an asset is recorded together with its
related long-term obligation to reflect the purchase and
financing.
All
other leases are accounted for as operating leases wherein
rental payments are expensed as incurred.
Lease
inducements represent leasehold improvement allowances and
reduced or free rent periods and are amortized on a
straight-line basis over the term of the lease and are
recorded as a reduction of rent expense.
Research
and development costs
Research
and development costs, including acquired in-process research
and development expenses for which there is no alternative
future use, are charged as an expense in the period in which
they are incurred.
Income
or loss per share
Income
or loss per share is calculated based on the weighted average
number of common shares outstanding. Diluted loss
per share does not differ from basic loss per share since the
effect of the Company’s stock options and warrants is
anti-dilutive. Diluted income per share is calculated using
the treasury stock method which uses the weighted average
number of common shares outstanding during the period and
also includes the dilutive effect of potentially issuable
common shares from outstanding, in-the-money stock options
and warrants.
The
following table sets out the computation of basic and diluted
net income (loss) per common share:
For
the year ended December 31, 2012, potential common shares of
1,085,503 were excluded from the calculation of income per
common share because their inclusion would be anti-dilutive
(December 31, 2011 –2,830,635; December 31, 2010
– 1,627,280).
Government
grants and refundable investment tax credits
Government
grants and tax credits provided for current expenses is
included in the determination of income or loss for the year,
as a reduction of the expenses to which it relates.
Government grants and tax credits towards the acquisition of
property and equipment is deducted from the cost of the
related property and equipment.
Foreign
currency translation
The
functional currency of the Company is the Canadian dollar.
For the Company and its integrated subsidiaries (Protiva
Biotherapeutics Inc. and Protiva Biotherapeutics (USA),
Inc.), foreign currency monetary assets and liabilities are
translated into Canadian dollars at the rate of exchange
prevailing at the balance sheet date. Non-monetary
assets and liabilities are translated at historical exchange
rates. The previous month’s closing rate of exchange is
used to translate revenue and expense
transactions. Exchange gains and losses are
included in income or loss for the period.
Deferred
income taxes
Income
taxes are accounted for using the asset and liability method
of accounting. Deferred income taxes are
recognized for the future income tax consequences
attributable to differences between the carrying values of
assets and liabilities and their respective income tax bases
and for loss carry-forwards. Deferred income tax
assets and liabilities are measured using enacted income tax
rates expected to apply to taxable income in the periods in
which temporary differences are expected to be recovered or
settled. The effect on deferred income tax assets
and liabilities of a change in tax laws or rates is included
in earnings in the period that includes the enactment
date. When realization of deferred income tax
assets does not meet the more-likely-than-not criterion for
recognition, a valuation allowance is provided.
Stock-based
compensation
The
Company grants stock options to employees and directors
pursuant to a share incentive plan described in note
6. Compensation expense is recorded for issued
stock options using the fair value method with a
corresponding increase in additional paid-in capital. Any
consideration received on the exercise of stock options is
credited to share capital.
The
fair value of stock options is typically measured at the
grant date and amortized on a straight-line basis over the
vesting period.
Warrants
The
Company accounts for the warrants under the authoritative
guidance on accounting for derivative financial instruments
indexed to, and potentially settled in, a company’s own
stock, on the understanding that in compliance with
applicable securities laws, the registered warrants require
the issuance of registered securities upon exercise and do
not sufficiently preclude an implied right to net cash
settlement. The Company classifies warrants in its
consolidated balance sheet as a liability which is revalued
at each balance sheet date subsequent to the initial
issuance. The Company uses the Black-Scholes pricing model to
value the warrants. Determining the appropriate fair-value
model and calculating the fair value of registered warrants
requires considerable judgment. A small change in the
estimates used may cause a relatively large change in the
estimated valuation. The estimated volatility of the
Company’s common stock at the date of issuance, and at
each subsequent reporting period, is based upon observations
of warrants in the market with similar characteristics and
expected remaining lives. The risk-free interest rate is
based on the zero-coupon rate for bonds with a maturity
similar to the expected remaining life of the warrants at the
valuation date. The expected life of the warrants is assumed
to be equivalent to their remaining contractual term.
Segment
information
The
Company operates in a single reporting segment, the research
and development of RNA interference
therapeutics. Substantially all of the
Company’s revenues to date were earned from customers
or collaborators based in the United States. Substantially
all of the Company’s premises, property and equipment
is located in Canada.
Recent
accounting pronouncements
From
time to time, new accounting pronouncements are issued by the
Financial Accounting Standards Board (FASB) or other standard
setting bodies that are adopted by the Company as of the
specified effective date. Unless otherwise discussed, we
believe that the impact of recently issued standards that are
not yet effective will not have a material impact on our
financial position or results of operations upon
adoption.
In
December 2011, the FASB issued ASU 2011-11, Balance Sheet
(Topic 210): Disclosures about Offsetting Assets and
Liabilities. This newly issued accounting standard
requires an entity to disclose both gross and net information
about instruments and transactions eligible for offset in the
balance sheet as well as instruments and transactions
executed under a master netting or similar arrangement and
was issued to enable users of financial statements to
understand the effects or potential effects of those
arrangements on its balance sheet. This ASU is required to be
applied retrospectively and is effective for fiscal years,
and interim periods within those years, beginning on or after
January 1, 2013. As this accounting standard only
requires enhanced disclosure, the adoption of this standard
is not expected to have an impact on the Company’s
financial position or statement of operations.
In
June 2011, the FASB issued ASU No. 2011-05, Comprehensive
Income (Topic 220): Presentation of Comprehensive
Income. This newly issued accounting standard
(1) eliminates the option to present the components of
other comprehensive income as part of the statement of
changes in stockholders’ equity; (2) requires the
consecutive presentation of the statement of net income and
other comprehensive income; and (3) requires an entity
to present reclassification adjustments on the face of the
financial statements from other comprehensive income to net
income. The amendments in this ASU do not change the items
that must be reported in other comprehensive income or when
an item of other comprehensive income must be reclassified to
net income nor do the amendments affect how earnings per
share is calculated or presented. In December 2011, the FASB
issued ASU No. 2011-12, Deferral of the
Effective Date for Amendments to the Presentation of
Reclassifications of Items Out of Accumulated Other
Comprehensive Income in Accounting Standards Update
No. 2011-05, which defers the requirement within
ASU 2011-05 to present on the face of the financial
statements the effects of reclassifications out of
accumulated other comprehensive income on the components of
net income and other comprehensive income for all periods
presented. During the deferral, entities should continue to
report reclassifications out of accumulated other
comprehensive income consistent with the presentation
requirements in effect prior to the issuance of ASU 2011-05.
These ASUs are required to be applied retrospectively and are
effective for fiscal years, and interim periods within those
years, beginning after December 15, 2011, which for the
Company means January 1, 2012. As these accounting
standards do not change the items that must be reported in
other comprehensive income or when an item of other
comprehensive income must be reclassified to net income, the
adoption of these standards did not have an impact on the
Company’s financial position or results of
operations.
In
February 2013, the FASB issued amendments to the accounting
guidance for presentation of comprehensive income to improve
the reporting of reclassifications out of accumulated other
comprehensive income. The amendments do not change the
current requirements for reporting net income or other
comprehensive income, but do require an entity to provide
information about the amounts reclassified out of accumulated
other comprehensive income by component. In addition, an
entity is required to present, either on the face of the
statement where the net income is presented or in the notes,
significant amounts reclassified out of accumulated other
comprehensive income by the respective line items of net
income but only if the amount reclassified is required under
GAAP to be reclassified to net income in its entirety in the
same reporting period. For other amounts that are not
required under GAAP to be reclassified in their entirety to
net income, an entity is required to cross-reference to other
disclosures required under GAAP that provide additional
detail about these amounts. For public companies, these
amendments are effective prospectively for reporting periods
beginning after December 15, 2012. We do not believe the
adoption of this guidance will have a material impact on our
consolidated financial statements.
In
May 2011, the FASB issued ASU No. 2011-04, Fair Value
Measurement (Topic 820): Amendments to Achieve Common Fair
Value Measurement and Disclosure Requirements in
U.S. GAAP and IFRSs. This newly issued accounting
standard clarifies the application of certain existing fair
value measurement guidance and expands the disclosures for
fair value measurements that are estimated using significant
unobservable (Level 3) inputs. This ASU is
effective on a prospective basis for annual and interim
reporting periods beginning on or after December 15,
2011, which for the Company means January 1, 2012. The
adoption of this standard did not have a material impact on
the Company’s financial position or results of
operations.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
The entire disclosure for all significant accounting policies of the reporting entity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 3 - Collaborations, contracts and licensing agreements
|
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2012
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Collaborative Arrangement Disclosure [Text Block] |
The
following tables set forth revenue recognized under
collaborations, contracts and licensing agreements:
The
following table sets forth deferred collaborations and
contracts revenue:
On
July 14, 2010, the Company signed a contract with the United
States Government to advance TKM-Ebola, an RNAi therapeutic
utilizing the Company’s lipid nanoparticle technology
to treat Ebola virus infection.
In
the initial phase of the contract, funded as part of the
Transformational Medical Technologies program, the Company is
eligible to receive up to US$34.7 million. This
initial funding is for the development of TKM-Ebola including
completion of preclinical development, filing an
Investigational New Drug application with the United States
Food and Drug Administration (“FDA”) and
completing a Phase 1 human safety clinical trial.
The
U.S. Government has the option of extending the contract
beyond the initial funding period to support the advancement
of TKM-Ebola through to the completion of clinical
development and FDA approval. Based on the contract’s
budget this would provide the Company with up to US$140.0
million in funding for the entire program.
Under
the contract, the Company is reimbursed for costs incurred,
including an allocation of overhead costs, and is paid an
incentive fee. At the beginning of the fiscal year the
Company estimates its labour and overhead rates for the year
ahead. At the end of the year the actual labour and overhead
rates are calculated and revenue is adjusted accordingly. The
Company’s actual labour and overhead rates will differ
from its estimated rates based on actual costs incurred and
the proportion of the Company’s efforts on contracts
and internal products versus indirect activities. Within
minimum and maximum collars, the amount of incentive fee the
Company can earn under the contract varies based on costs
incurred versus budgeted costs. Until the Company is able to
make a reliable estimate of the final contract costs, only
the minimum incentive fee achievable and earned is
recognized.
On
August 6, 2012, the Company announced that it had received a
temporary stop-work order from the U.S. Government in respect
of this contract. On October 2, 2012, the Company announced
that the stop-work order had been lifted and work on the
contract resumed. On November 1, 2012, the Company submitted
a contract modification request to the U.S. Government in
order to integrate recent advancements in the Company’s
formulation technology. The modification request is currently
being negotiated while work is continuing on the
contract.
License
and Collaboration Agreement with Alnylam through
Tekmira
On
January 8, 2007, the Company entered into a licensing and
collaboration agreement with Alnylam (“Alnylam License
and Collaboration”), which was amended and restated in
May 2008, giving them an exclusive license to certain of the
Company’s historical lipid nanoparticle intellectual
property for the discovery, development, and
commercialization of ribonucleic acid interference
(“RNAi”) therapeutics.
The
Alnylam License and Collaboration was replaced by a new
license agreement as part of the settlement which is
discussed below.
Cross-License
with Alnylam acquired through Protiva
As
a result of the acquisition of Protiva on May 30, 2008, the
Company acquired a Cross-License Agreement between Protiva
and Alnylam (the “Alnylam Cross-License”).
Alnylam was granted a non-exclusive license to the Protiva
intellectual property.
The
Alnylam Cross-License was replaced by a new license agreement
as part of the settlement which is discussed below.
Manufacturing
agreement with Alnylam
Under
a manufacturing agreement with Alnylam (the “Alnylam
Manufacturing Agreement”) effective January 1, 2009,
the Company was the exclusive manufacturer of any products
required by Alnylam through to the end of Phase 2 clinical
trials that utilize the Company’s technology. Alnylam
was paying the Company for the provision of staff and for
external costs incurred. Time charged to Alnylam was at a
fixed rate and under the Alnylam Manufacturing Agreement
there was a contractual minimum for the provision of staff of
$11,200,000 over the three year period ending December 31,
2011.
The
Alnylam Manufacturing Agreement was terminated as part of the
settlement which is discussed below.
Milestone
payments
In
June 2012 the Company earned a $1,018,100 (US$1,000,000)
milestone from Alnylam in respect of the initiation of
Alnylam’s ALN-TTR02 Phase 2 human clinical
trial.
Settlement
of litigation with Alnylam and AlCana Technologies Inc.
(“AlCana”)
On
March 16, 2011 the Company filed a complaint against Alnylam.
On November 12, 2012, the Company entered into an agreement
to settle all litigation between the Company and Alnylam and
AlCana (the “Settlement”) and also entered into a
new licensing agreement with Alnylam that replaces all
earlier licensing, cross-licensing, collaboration, and
manufacturing agreements. The Company expects to enter into a
separate cross license agreement with AlCana which will
include milestone and royalty payments and AlCana has agreed
not to compete in the RNAi field for five years. In
conjunction with the Settlement, the Company paid AlCana
$298,080 (US$300,000). A further $1,492,350 (US$1,500,000)
(see note 11), which the Company expects to pay upon the
execution of a cross license agreement with AlCana, was
included in research, development, collaborations and
contracts expenses in the year ended December 31, 2012
.
As
a result of the new Alnylam license agreement, on November
26, 2012, the Company received $65,039,000 (US$65,000,000) in
cash from Alnylam. This includes US$30,000,000 associated
with the termination of the manufacturing agreement and
US$35,000,000 associated with the termination of the previous
license agreements, as well as a modification of the
milestone and royalty schedules associated with Alnylam's
ALN-VSP, ALN-PCS, and ALN-TTR programs. In addition, Alnylam
has transferred all agreed upon patents and patent
applications related to lipid nanoparticle
(“LNP”) technology for the systemic delivery of
RNAi therapeutic products, including the MC3 lipid family, to
the Company, who will own and control prosecution of this
intellectual property portfolio. The Company is the only
entity able to sublicense its LNP intellectual property in
future platform-type relationships. Alnylam has a license to
use the Company’s intellectual property to develop and
commercialize products and may only grant access to the
Company’s LNP technology to its partners if it is part
of a product sublicense. Alnylam will pay the Company
milestones and royalties as Alnylam’s LNP-enabled
products are developed and commercialized.
The
new licensing agreement with Alnylam also grants the Company
intellectual property rights to develop its own proprietary
RNAi therapeutics. Alnylam has granted the Company a
worldwide license for the discovery, development and
commercialization of RNAi products directed to thirteen gene
targets – three exclusive and ten non-exclusive
licenses – provided that they have not been committed
by Alnylam to a third party or are not otherwise unavailable
as a result of the exercise of a right of first refusal held
by a third party or are part of an ongoing or planned
development program of Alnylam. Licenses for five of the ten
non-exclusive targets – ApoB, PLK1, Ebola, WEE1, and
CSN5 – have already been granted, along with an
additional license for ALDH2, which has been granted on an
exclusive basis. In consideration for this license, the
Company has agreed to pay single-digit royalties to Alnylam
on product sales and have milestone obligations of up to
US$8,500,000 on the non-exclusive licenses (with the
exception of TKM-Ebola, which has no milestone obligations).
Alnylam no longer has “opt-in” rights to the
Company’s lead oncology product, TKM-PLK1, so the
Company now holds all development and commercialization
rights related TKM-PLK1. The Company will have no milestone
obligations on the three exclusive licenses.
As
a result of the settlement of the litigation between the
Company and Alnylam, $18,618,043 (US$18,737,966) in a
contingent obligation payment to Orrick, Herrington and
Sutcliffe LLP (“Orrick”), lead legal counsel for
the lawsuit against Alnylam and AlCana, was paid out on
December 10, 2012 and recorded as other income
(losses).
On
May 10, 2010 the Company announced the expansion of its
research collaboration with BMS. Under the new agreement, BMS
uses small interfering RNA (“siRNA”) molecules
formulated by the Company in LNP technology to silence target
genes of interest. BMS is conducting the
preclinical work to validate the function of certain genes
and share the data with the Company. The Company
can use the preclinical data to develop RNAi therapeutic
drugs against the therapeutic targets of
interest. The Company received $3,233,400
(US$3,000,000) from BMS concurrent with the signing of the
agreement and recorded the amount as deferred revenue. The
Company is required to provide a pre-determined number of LNP
batches over the four-year agreement. BMS has a
first right to negotiate a licensing agreement on certain
RNAi products developed by the Company that evolve from BMS
validated gene targets.
Revenue
from the May 10, 2010 agreement with BMS is being recognized
as the Company produces the related LNP batches.
On
May 11, 2009 the Company announced a product development
agreement with F. Hoffman-La Roche Ltd (the “Roche
Product Development Agreement”). Under the Roche
Product Development Agreement Roche was to pay the Company up
to US$8,800,000 to support the advancement of each Roche RNAi
product candidate using the Company’s lipid
nanoparticle technology through to the filing of an
Investigational New Drug (“IND”)
application.
Under
the Roche Product Development Agreement Roche was paying the
Company for the provision of staff and for external costs
incurred. The Company recognized revenue in proportion to the
services provided up to the reporting date by comparing
actual hours spent to estimated total hours for each product
under the contract. Revenue from external costs incurred on
Roche product candidates was recorded in the period that
Roche was invoiced for those costs. The difference between
service revenue recognized and cash received was recorded in
the Company’s balance sheet as deferred revenue.
On
November 17, 2010, Roche announced that, as part of a
corporate restructuring, they would discontinue research and
development in the field of RNAi. Following the announcement
Roche confirmed that, except for completing some product
stability studies, they would be discontinuing product
development with the Company. The stability studies were
completed in 2011 and the Company has no further obligation
to Roche.
The
Company has active research agreements with a number of other
RNAi collaborators.
On
May 6, 2006, the Company signed a number of agreements with
Talon including the grant of worldwide licenses (the
“Talon License Agreement”) for three of the
Company’s chemotherapy products, Marqibo®,
AlocrestTM
(Optisomal Vinorelbine) and BrakivaTM
(Optisomal Topotecan).
On
May 27, 2009, the Talon License Agreement was amended to
decrease the size of near-term milestone payments and
increase the size of long-term milestone payments. On
September 20, 2010, the Talon License Agreement was amended a
second time such that Talon paid $5,916,750 (US$5,750,000) in
consideration for reducing certain future payments associated
with the product candidates. The payment of $5,916,750 was
recorded as license amendment revenue. If Talon sublicenses
any of the product candidates, the Company is eligible to
receive a percentage of any upfront fees or milestone
payments received by Talon.
The
Company had a contingent obligation that arose through a
Purchase and Settlement Agreement dated June 20, 2006 whereby
the Company retired exchangeable and development notes in
exchange for contingent consideration including certain
future milestone and royalty payments from Talon. Concurrent
with signing the second amendment of the Talon License
Agreement the Company signed a Waiver and Release with
certain contingent creditors, the “Former
Noteholders”. The balance of the contingent obligation
related to the Talon milestones and royalties immediately
prior to signing the Waiver and Release was US$22,835,476. As
per the terms of the Waiver and Release, in 2010, the Company
paid the Former Noteholders $5,916,750 (US$5,750,000) in full
settlement of the contingent obligation and recorded the
payment as a loss on the purchase and settlement of the
exchangeable and development notes. From the date of the
Waiver and Release, the Company has no further obligation to
the Former Noteholders and will retain any milestones or
royalties received from Talon.
On
August 9, 2012, the Company announced that Talon had received
accelerated approval for Marqibo® from the FDA for the
treatment of adult patients with Philadelphia chromosome
negative acute lymphoblastic leukemia in second or greater
relapse or whose disease has progressed following two or more
anti-leukemia therapies. Marqibo is a liposomal formulation
of the chemotherapy drug vincristine. In the year ended
December 31, 2012, the Company received a milestone of
$992,000 (US$1,000,000) based on the FDA’s approval of
Marqibo and will receive royalty payments based on
Marqibo’s commercial sales. There are no further
milestones related to Marqibo but the Company is eligible to
receive total milestone payments of up to US$18,000,000 on
Alocrest and Brakiva.
As
a result of the acquisition of Protiva in 2008, the Company
received a non-exclusive royalty-bearing world-wide license,
of certain intellectual property acquired by Merck. Under the
license Merck will pay up to US$17,000,000 in milestones for
each product it develops using the acquired intellectual
property except for the first product for which Merck will
pay up to US$15,000,000 in milestones. Merck will also pay
royalties on product sales. The license agreement with Merck
was entered into as part of a settlement of litigation
between Protiva and a Merck subsidiary. No payments have been
made under this license to date.
Merck
has granted a license to the Company to certain of its
intellectual property.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 4 - Property and equipment
|
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2012
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Property, Plant and Equipment Disclosure [Text Block] |
In
the year ended December 31, 2012, the Company identified
certain property and equipment that is not currently in use.
All of this property and equipment had been fully depreciated
and had a net book value of zero. The cost and accumulated
depreciation of this property and equipment of $5,574,219 was
removed from the Company’s balance sheet on December
31, 2012.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
The entire disclosure for long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software. This disclosure may include property plant and equipment accounting policies and methodology, a schedule of property, plant and equipment gross, additions, deletions, transfers and other changes, depreciation, depletion and amortization expense, net, accumulated depreciation, depletion and amortization expense and useful lives, income statement disclosures, assets held for sale and public utility disclosures. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 5 - Borrowing Facility
|
12 Months Ended | ||
|---|---|---|---|
|
Dec. 31, 2012
|
|||
| Debt Disclosure [Text Block] |
On
December 21, 2011, the Company signed an agreement with
Silicon Valley Bank (“SVB”) for a term loan
facility (the “loan”) of up to $3,051,000
(US$3,000,000). On September 24, 2012 the loan was amended to
extend the deadline for any draw down on the facility from
September 30, 2012 to December 31, 2012. The loan
would have matured on September 1, 2015 and would have
carried fixed interest rate of 8% annually. The Company did
not draw down on the loan and the facility has now
expired.
In
part payment for establishing the loan, the Company issued
SVB 54,545 common share purchase warrants with an exercise
price of $1.65 and an expiration date of December 21, 2018.
On the date of issuance, the Black-Scholes aggregate value of
the 54,545 warrants was $35,004 and is based on an assumed
risk-free interest rate of 1.48%, volatility of 40%, a zero
dividend yield and an expected life of 7 years. The fair
value of the warrants at issuance was recorded as a
liability.
At
December 31, 2011, the Black-Scholes value of the warrants
was $35,004, based on an assumed risk-free interest rate of
1.51%, volatility of 40%, a zero dividend yield and an
expected life of 6.98 years.
The
54,545 warrants were exercised by SVB during the year ended
December 31, 2012 (note 6 (d)).
The
legal and professional costs of establishing the loan of
$70,095 and the initial fair value of the warrants of $35,004
are included in general and administrative expenses in the
year ended December 31, 2011.
|
| X | ||||||||||
|
- Definition
The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 6 - Share Capital
|
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2012
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stockholders' Equity Note Disclosure [Text Block] |
On
June 16, 2011, the Company completed a public offering of
1,789,900 units at a price of $2.85 each for total gross
proceeds, before expenses, of $5,101,215. Each unit consists
of one common share and one half of one common share purchase
warrant. Each whole warrant entitles the holder to acquire
one common share at a price of $3.35. The warrants expire on
June 15, 2016. After paying underwriter’s commission
and other unit issue costs, the offering generated net cash
of $4,545,647. The total unit issuance cost of $555,568 has
been allocated, on a pro-rata basis, as $475,568 to the
shares and $80,000 to the warrants and recorded,
respectively, to share capital and warrant issuance costs in
the consolidated statement of operations and comprehensive
income (loss).
On
the date of issuance, the Black-Scholes aggregate value of
the 894,950 warrants was $742,809 based on an assumed
risk-free interest rate of 2.19%, volatility of 40%, a zero
dividend yield and an expected life of 5 years. The
fair value of the warrants at issuance was initially
recorded as a liability with the residual amount of
proceeds allocated to share capital.
On
February 29, 2012, the Company completed a private placement
offering of 1,848,601 units at a price of $2.20 each for
total gross proceeds, before expenses, of $4,066,923. Each
unit consists of one common share and one half of one common
share purchase warrant. Each whole warrant entitles the
holder to acquire one common share at a price of $2.60. The
warrants expire on February 28, 2017. After paying brokerage
fees and other unit issue costs, the offering generated net
cash of $3,841,516. The total unit issuance cost of $225,407
has been allocated, on a pro-rata basis, as $178,407 to the
shares and $47,000 to the warrants and recorded,
respectively, to share capital and warrant issuance costs in
the consolidated statement of operations and comprehensive
income (loss).
On
the date of issuance, the Black-Scholes aggregate value of
the 924,302 warrants was $850,358 based on an assumed
risk-free interest rate of 1.44%, volatility of 40%, a zero
dividend yield and an expected life of 5 years. The fair
value of the warrants at issuance was initially recorded as a
liability with the residual amount of proceeds from the
private placement being allocated to share capital.
The
Company’s authorized share capital consists of an
unlimited number of common and preferred shares without par
value.
On
November 4, 2010 the Company’s common shares were
consolidated on a basis of five current common shares for one
new common share. All references to common stock,
common shares outstanding, average number of common shares
outstanding, per share amounts and options in these financial
statements and notes thereto have been restated to reflect
the common stock consolidation on a retroactive basis.
During
the year ended December 31, 2012, there were 230,841 warrants
exercised for $631,874 in cash and 54,545 warrants exercised
using the cashless exercise provision in return for 38,644
common shares (year ended December 31, 2011 –
nil).
A
following table summarizes the Company’s warrant
activity for the years ended December 31, 2011 and
2012:
The
aggregate intrinsic value in the table above is calculated
based on the difference between the exercise price of the
warrants and the quoted price of the Company’s common
stock as of the reporting date.
All
of the Company’s warrants were exercisable as of
December 31, 2012.
The
weighted average Black-Scholes option-pricing assumptions and
the resultant fair values are as follows for warrants
outstanding at December 31, 2012 and 2011 are as
follows:
The
value of the Company’s warrants are particularly
sensitive to changes in the Company’s share price and
the estimated rate of share price volatility.
The
Company has three share-based compensation plans; the
“2007 Plan”, the “2011 Plan” and the
“Protiva Option Plan”.
On
June 22, 2011, the shareholders of the Company approved an
omnibus stock-based compensation plan (the “2011
Plan”) and a 273,889 increase in the number of
stock-based compensation awards that the Company is permitted
to issue. The Company’s pre-existing 2007 Plan was
limited to the granting of stock options as equity incentive
awards whereas the 2011 Plan also allows for the issuance of
tandem stock appreciation rights, restricted stock units and
deferred stock units (collectively, and including options,
referred to as “Awards”). The 2011 Plan replaces
the 2007 Plan. The 2007 Plan will continue to govern the
options granted thereunder. No further options will be
granted under the Company’s 2007 Plan.
Under
the Company’s 2007 Plan the Board of Directors granted
options to employees, directors and consultants of the
Company. The exercise price of the options was
determined by the Company’s Board of Directors but was
always at least equal to the closing market price of the
common shares on the day preceding the date of grant and the
term of options granted did not exceed 10
years. The options granted generally vested over
three years for employees and immediately for
directors.
Under
the Company’s 2011 Plan the Board of Directors may
grant options, and other types of Awards, to employees,
directors and consultants of the Company. The
exercise price of the options is determined by the
Company’s Board of Directors but will be at least equal
to the closing market price of the common shares on the day
preceding the date of grant and the term may not exceed 10
years. Options granted generally vest over
three years for employees and immediately for
directors.
Hereafter,
information on options governed by the 2007 Plan and 2011
Plan is presented on a consolidated basis as the terms of the
two plans are similar. Information on the Protiva Option Plan
is presented separately.
On
June 20, 2012, the shareholders of the Company approved a
550,726 increase in the number of stock-based compensation
awards that the Company is permitted to issue.
Stock
option activity for the Company’s 2007 Plan and 2011
Plan
Options
under the 2007 Plan and 2011 Plan expire at various dates
from December 5, 2013 to December 9, 2022.
The
following table summarizes information pertaining to stock
options outstanding at December 31, 2012 under the
Company’s 2007 Plan and 2011 Plan:
At
December 31, 2012, there were 1,315,155 options exercisable
(December 31, 2011 – 1,015,224; December 31, 2010 -
861,549) with a weighted average exercise price of $4.75. The
weighted average remaining contractual life of exercisable
options as at December 31, 2012 was 6.3 years. The aggregate
intrinsic value of options exercisable at December 31, 2012
was $1,834,841.
A
summary of the Company’s non-vested stock option
activity and related information for the year ended December
31, 2012 is as follows:
The
weighted average remaining contractual life for options
expected to vest at December 31, 2012 was 9.2 years and the
weighted average exercise price for these options was $3.69
per share.
The
aggregate intrinsic value of options expected to vest as at
December 31, 2012 was $450,330 (December 31, 2011 - $nil;
December 31, 2010 - $175,905).
The
total fair value of options that vested during the year ended
December 31, 2012 was $1,071,548 (2011 - $351,542; 2010 -
$468,105).
Valuation
assumptions for the Company’s 2007 Plan and 2011
Plan
The
fair value of stock options at date of grant, based on the
following assumptions, was estimated using the Black-Scholes
option-pricing model. Assumptions on the dividend yield are
based on the fact that the Company has never paid cash
dividends and has no present intention to pay cash dividends.
Assumptions about the Company’s expected stock-price
volatility are based on the historical volatility of the
Company’s publicly traded stock. The risk-free interest
rate used for each grant is equal to the zero coupon rate for
instruments with a similar expected life. Expected life
assumptions are based on the Company’s historical data.
The Company currently expects, based on an analysis of its
historical forfeitures, that no options will be forfeited by
senior employees and that approximately 94% of its options
issued to non-senior employees will ultimately vest, and
based on a three year vesting period has applied an annual
forfeiture rate of 2.0% to all unvested options held by
non-senior employees as of December 31, 2012. The Company
will record additional expense if the actual forfeitures are
lower than estimated and will record a recovery of prior
expense if the actual forfeitures are higher than estimated.
The weighted average option pricing assumptions and the
resultant fair values are as follows:
Stock-based
compensation expense for the Company’s 2007 Plan and
2011 Plan
An
expense for stock-based compensation for options awarded to
employees and calculated in accordance with the fair value
method has been recorded in the consolidated statement of
operations and comprehensive income (loss) as follows:
At
December 31, 2012, there remains $952,149 of unearned
compensation expense related to unvested employee stock
options to be recognized as expense over a weighted-average
period of approximately 15 months.
Protiva
Option Plan
On
May 30, 2008, as a condition of the acquisition of Protiva
Biotherapeutics Inc., a total of 350,457 common shares of the
Company were reserved for the exercise of 519,073 Protiva
share options (“Protiva Options”). The Protiva
Options have an exercise price of $0.30, were fully vested
and exercisable as of May 30, 2008, expire at various dates
from January 22, 2013 to March 1, 2018 and upon exercise each
option will be converted into approximately 0.6752 shares of
the Company (the same ratio at which Protiva common shares
were exchanged for Company common shares at completion of the
acquisition of Protiva). The Protiva Options are not part of
the Company’s 2007 Plan or 2011 Plan and the Company is
not permitted to grant any further Protiva Options.
The
following table sets forth outstanding options under the
Protiva Option Plan:
The
weighted average remaining contractual life of exercisable
Protiva Options as at December 31, 2012 was 3.1 years.
The
aggregate intrinsic value of Protiva Options outstanding at
December 31, 2012 was $1,457,269. The intrinsic value of
Protiva Options exercised in the year ended December 31, 2012
was $18,929 (2011 - $42,615; 2010 - $2,688).
Awards
outstanding and available for issuance
Combining
all of the Company’s share-based compensation plans, at
December 31, 2012, the Company has 1,970,145 options
outstanding and a further 422,688 Awards available for
issuance.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable). Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 7 - Government Grants and Refundable Investment Tax Credits
|
12 Months Ended | ||
|---|---|---|---|
|
Dec. 31, 2012
|
|||
| Government Grants And Refundable Investment Tax Credits [Text Block] |
Government
grants and refundable investment tax credits have been netted
against research and development expenses.
Government
grants for the year ended December 31, 2012 include $nil in
funding from the US Army Medical Research Institute for
Infectious Diseases (2011 - $nil; 2010 - $191,194).
The
Company’s estimated claim for refundable Scientific
Research and Experimental Development investment tax credits
for the year ended December 31, 2012 is $nil (2011 - $20,905;
2010 - $196,556).
|
| X | ||||||||||
|
- Definition
The entire disclosure for information about government grants and investment tax credits netted against expenses in the statement of operations. No definition available.
|
|
Note 8 - Income taxes - outstanding
|
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2012
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Income Tax Disclosure [Text Block] |
Income
tax (recovery) expense varies from the amounts that would be
computed by applying the combined Canadian federal and
provincial income tax rate of 17.5% (year ended December 31,
2011 – 26.5%; December 31, 2010 – 28.5%) to the
loss before income taxes as shown in the following
tables:
As
at December 31, 2012, the Company has investment tax credits
available to reduce Canadian federal income taxes of
$5,861,202 (December 31, 2011 - $11,093,450) and provincial
income taxes of $1,904,908 (December 31, 2011 - $5,500,315)
and expiring between 2013 and 2032.
At
December 31, 2012, the Company has scientific research and
experimental development expenditures of $48,111,776
(December 31, 2011 - $50,575,034) available for indefinite
carry-forward and $21,348,573 (December 31, 2011 -
$19,037,156) of net operating losses due to expire between
2027 and 2032 and which can be used to offset future taxable
income in Canada.
On
November 23, 2011, the Company was registered as a
corporation under the Business Activity Act in the province
of British Columbia. Under this program, provincial
corporation tax charged on foreign income earned from the
Company’s patents will be eligible for a 75% tax refund
up to a maximum of $8,000,000.
Significant
components of the Company’s deferred tax assets are
shown below:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 9 - Contingencies and commitments
|
12 Months Ended | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2012
|
||||||||||||||||||||||||||||
| Commitments and Contingencies Disclosure [Text Block] |
Property
lease
Effective
July 29, 2009 the Company signed an amendment to the
operating lease for its laboratory and office premises. The
amended lease expires in July 2014 but the Company has the
option to extend the lease to 2017 and then to 2022 and then
to 2027. The amended lease included a signing incentive
payment. In accordance with the Company’s accounting
policy the signing incentive payment is being amortized on a
straight-line basis over the term of the amended
lease.
Following
the lease amendment the minimum commitment for rent and
estimated operating costs, are as follows:
The
Company’s lease expense, net of sub-lease income, for
the year ended December 31, 2012 of $936,760 has been
recorded in the consolidated statements of operations and
comprehensive loss in research, development, collaborations
and contracts and general and administrative expenses (2011 -
$933,528; 2010 - $931,606).
The
Company has netted $171,923 of sub-lease income against lease
expense in the year ended December 31, 2012 (year ended
December 31, 2011 - $194,281; 2010 - $194,281).
The
Company’s sub-lease agreement ended in December
2012.
Product
development partnership with the Canadian Government
The
Company entered into a Technology Partnerships Canada ("TPC")
agreement with the Canadian Federal Government on November
12, 1999. Under this agreement, TPC agreed to fund
27% of the costs incurred by the Company, prior to March 31,
2004, in the development of certain oligonucleotide product
candidates up to a maximum contribution from TPC of
$9,329,912. As at December 31, 2012, a cumulative
contribution of $3,701,571 has been received and the Company
does not expect any further funding under this
agreement. In return for the funding provided by
TPC, the Company agreed to pay royalties on the share of
future licensing and product revenue, if any, that is
received by the Company on certain non-siRNA oligonucleotide
product candidates covered by the funding under the
agreement. These royalties are payable until a
certain cumulative payment amount is achieved or until a
pre-specified date. In addition, until a
cumulative amount equal to the funding actually received
under the agreement has been paid to TPC, the Company agreed
to pay low single digit percentage royalties on any royalties
the Company receives for Marqibo. To December 31, 2012 the
Company had not made any royalty payments to TPC.
Contingently
payable promissory notes
On
March 25, 2008, Protiva declared dividends totaling
US$12,000,000. The dividends were paid by Protiva issuing
promissory notes on May 23, 2008. Recourse against Protiva
for payment of the promissory notes will be limited to
Protiva’s receipt, if any, of up to US$12,000,000 in
license payments from Merck (see note 3(g)). Protiva will pay
these funds if and when it receives them, to the former
Protiva shareholders in satisfaction of the promissory notes.
As contingent items the US$12,000,000 receivable and the
related promissory notes payable are not recorded in the
Company’s consolidated balance sheet.
License
and collaboration agreement with Halo-Bio RNAi Therapeutics,
Inc. (“Halo-Bio”)
On
August 24, 2011, the Company entered into a license and
collaboration agreement with Halo-Bio. Under the agreement,
Halo-Bio granted the Company an exclusive license to its
multivalent ribonucleic acid (“MV-RNA”)
technology. The agreement provides for the companies to
work together to design and develop MV-RNA molecules to
gene targets of interest to the Company and to combine
MV-RNA molecules with the Company’s LNP technology to
develop therapeutic products.
The
Company paid Halo-Bio an initial license fee of $97,940
(US$100,000) and recorded this amount as a research,
development, collaborations and contracts expense in the
year ended December 31, 2011.
The
agreement was amended on August 8, 2012 to adjust the future
license fees and other contingent payments. The
Company recorded a further $447,780 (US$450,000) in license
fees to research, development, collaborations and contracts
expense in the year ended December 31, 2012, in respect of
the agreement. Under the amended agreement, as at December
31, 2012, the maximum future license fees are US$1,300,000.
The Company will pay up to US$12,700,000 in milestones on
each product developed plus royalties.
License
agreement with Marina Biotech, Inc.
(“Marina”)
On
November 29, 2012 the Company announced a worldwide,
non-exclusive license to a novel RNAi payload technology
called Unlocked Nucleobase Analog (“UNA”) from
Marina for the development of RNAi therapeutics.
UNA
technology can be used in the development of RNAi
therapeutics, which treat disease by silencing specific
disease causing genes. UNAs can be incorporated into RNAi
drugs and have the potential to improve them by increasing
their stability and reducing off-target effects.
Under
the license agreement the Company paid Marina an upfront fee
of $298,098 (US$300,000). A further license payment of
US$200,000 is due in 2013 and the Company will make milestone
payments of up to US$3,250,000 and royalties on each product
developed by the Company that uses Marina’s UNA
technology. The upfront fee was recorded to research,
development, collaborations and contracts expense in the year
ended December 31, 2012.
|
|||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
The entire disclosure for commitments and contingencies. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 10 - Concentrations of business risk
|
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2012
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Concentration Risk Disclosure [Text Block] |
Credit
risk
Credit
risk is defined by the Company as an unexpected loss in cash
and earnings if a collaborative partner is unable to pay its
obligations in due time. The Company’s main
source of credit risk is related to its accounts receivable
balance which principally represents temporary financing
provided to collaborative partners in the normal course of
operations. Accounts receivable from the U.S. Government as
at December 31, 2012 were $947,802 and represent 89% of total
accounts receivable as at that date (December 31, 2011 -
$747,720 and 85%).
The
Company does not currently maintain a provision for bad debts
as the majority of accounts receivable are from collaborative
partners or government agencies and are considered low
risk.
The
carrying amount of financial assets represents the maximum
credit exposure. The maximum exposure to credit risk at
December 31, 2012 was the accounts receivable balance of
$1,069,437 (December 31, 2011 - $880,693).
All
accounts receivable balances were current as at December 31,
2012 and December 31, 2011.
Significant
collaborators and customers risk
We
depend on a small number of collaborators and customers for a
significant portion of our revenues (see note 3).
Liquidity
Risk
Liquidity
risk results from the Company’s potential inability to
meet its financial liabilities, for example payments to
suppliers. The Company ensures sufficient
liquidity through the management of net working capital and
cash balances.
The
Company’s liquidity risk is primarily attributable to
its cash and cash equivalents. The Company limits exposure to
liquidity risk on its liquid assets through maintaining its
cash and cash equivalent deposits with high-credit quality
financial institutions. Due to the nature of these
investments, the funds are available on demand to provide
optimal financial flexibility.
The
Company believes that its current sources of liquidity are
sufficient to cover its likely applicable short term cash
obligations. The Company’s financial obligations
include accounts payable and accrued liabilities which
generally fall due within 45 days.
The
net liquidity of the Company is considered to be the cash and
cash equivalents less accounts payable and accrued
liabilities.
Foreign
currency risk
The
Company’s revenues and operating expenses are
denominated in both Canadian and US dollars so the results of
the Company’s operations are subject to currency
transaction and translation risk.
The
operating results and financial position of the Company are
reported in Canadian dollars in the Company’s financial
statements. The fluctuation of the US dollar in relation to
the Canadian dollar will consequently have an impact upon the
Company’s income or loss and may also affect the value
of the Company’s assets and the amount of
shareholders’ equity.
The
Company manages its US dollar exchange rate risk by, whenever
possible, using cash received from US dollar revenues to pay
US dollar expenses and by limiting its holdings of US dollar
cash and cash equivalent balances to working capital levels.
The Company used a forward exchange contract to convert
US$45,000,000 into Canadian dollars in November 2012. The
Company has not entered into any other agreements or
purchased any instruments to hedge possible currency
risks.
The
Company’s exposure to US dollar currency expressed in
Canadian dollars was as follows:
An
analysis of the Company’s sensitivity to foreign
currency exchange rate movements is not provided in these
financial statements as a large proportion of the
Company’s foreign currency purchases are reimbursed by
collaborators and customers which mitigates the
Company’s foreign currency risk; therefore, the impact
on the Company is not material.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 11 - Supplementary information
|
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2012
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Supplemental Balance Sheet Disclosures [Text Block] |
Accounts
payable and accrued liabilities is comprised of the
following:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity. No definition available.
|
|
Accounting Policies, by Policy (Policies)
|
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2012
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Description and Basis of Presentation [Text Block] | Basis
of presentation
Tekmira
Pharmaceuticals Corporation was incorporated on October 6,
2005 as an inactive wholly owned subsidiary of Inex
Pharmaceuticals Corporation
(“Inex”). Pursuant to a “Plan of
Arrangement” effective April 30, 2007 the business and
substantially all of the assets and liabilities of Inex were
transferred to the Company. The consolidated financial
statements for all periods presented herein include the
consolidated operations of Inex until April 30, 2007 and the
operations of the Company thereafter.
These
consolidated financial statements include the accounts of the
Company and its two wholly-owned subsidiaries, Protiva
Biotherapeutics Inc. and Protiva Biotherapeutics (USA), Inc.,
which were acquired on May 30, 2008. All intercompany
transactions and balances have been eliminated on
consolidation |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Use of Estimates, Policy [Policy Text Block] | Use
of estimates
The preparation of
the consolidated financial statements in conformity with
generally accepted accounting principles requires management
to make estimates and assumptions about future events that
affect the reported amounts of assets, liabilities, revenue,
expenses, contingent assets and contingent liabilities as at
the end or during the reporting period. Actual
results could significantly differ from those
estimates. Significant areas requiring the use of
management estimates relate to recognition of revenue,
stock-based compensation, share purchase warrant valuation
and the amounts recorded as accrued
liabilities. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cash and Cash Equivalents, Policy [Policy Text Block] | Cash
and cash equivalents
Cash
and cash equivalents are all highly liquid instruments with
an original maturity of three months or less when
purchased. Cash equivalents are recorded at cost
plus accrued interest. The carrying value of these cash
equivalents approximates their fair value. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fair Value Measurement, Policy [Policy Text Block] | Fair
value of financial instruments
We
measure certain financial instruments and other items at fair
value.
To
determine the fair value, we use the fair value hierarchy for
inputs used in measuring fair value that maximizes the use of
observable inputs and minimizes the use of unobservable
inputs by requiring that the most observable inputs be used
when available. Observable inputs are inputs market
participants would use to value an asset or liability and are
developed based on market data obtained from independent
sources. Unobservable inputs are inputs based on assumptions
about the factors market participants would use to value an
asset or liability. The three levels of inputs that may be
used to measure fair value are as follows:
Assets
and liabilities are classified based on the lowest level of
input that is significant to the fair value measurements.
Changes in the observability of valuation inputs may result
in a reclassification of levels for certain securities within
the fair value hierarchy.
The
Company’s financial instruments consist of cash and
cash equivalents, accounts receivable, investment tax credits
receivable, accounts payable and accrued liabilities,
warrants and promissory notes.
The
carrying values of cash and cash equivalents are recorded at
fair value based on quoted prices in active markets. The
carrying values of accounts receivable, investment tax
credits receivable and accounts payable and accrued
liabilities approximate their fair values due to the
immediate or short-term maturity of these financial
instruments.
As
quoted prices for the warrants are not readily available, the
Company has used a Black-Scholes pricing model, as described
in Notes 5 and 6, to estimate fair value. These are level 3
inputs as defined above.
The
following tables present information about the
Company’s assets and liabilities that are measured at
fair value on a recurring basis, and indicates the fair value
hierarchy of the valuation techniques used to determine such
fair value:
The
following table presents the changes in fair value of the
Company’s warrants:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventory, Policy [Policy Text Block] | Inventory
Inventory
includes materials assigned for the manufacture of products
for collaborative partners and manufacturing costs for
products awaiting acceptance by collaborative partners.
Inventory is carried at the lower of cost and net realizable
value. The cost of inventories includes all costs of
purchase, costs of manufacturing and other costs incurred in
bringing the inventories to their present location and
condition.
Materials
purchased for the Company’s own research and
development products, or, for collaborative partners where an
acceptance criteria does not apply, are not recorded as
inventory but are expensed at the time of receipt. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Property, Plant and Equipment, Policy [Policy Text Block] | Property
and equipment
Property
and equipment is recorded at cost less impairment losses,
accumulated depreciation, related government grants and
investment tax credits. The Company records
depreciation using the straight-line method over the
estimated useful lives of the capital assets as
follows:
Leasehold
improvements are depreciated over their estimated useful
lives but in no case longer than the lease term, except where
lease renewal is reasonably assured. Assets held under
capital leases that do not allow for ownership to pass to the
Company are depreciated using the straight-line method over
their useful life, not exceeding the lease term. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Intangible Assets, Finite-Lived, Policy [Policy Text Block] | Intangible
assets
The
costs incurred in establishing and maintaining patents for
intellectual property developed internally are expensed in
the period incurred |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] | Impairment
of long-lived assets
If
there is a major event indicating that the carrying value of
property and equipment may be impaired then management will
perform an impairment test and if the recoverable value,
based on undiscounted future cash flows, exceeds carrying
value then such assets are written down to their fair
values |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Revenue Recognition, Policy [Policy Text Block] | Revenue
recognition
The Company earns
revenue from research and development collaboration and
contract services, licensing fees and milestone
payments. Revenues associated with multiple element
arrangements are attributed to the various elements based on
their relative fair values or are recognized as a single unit
of accounting when relative fair values are not determinable.
Non-refundable payments received under collaborative research
and development agreements are recorded as revenue as
services are performed and related expenditures are
incurred. Non-refundable upfront license
fees from collaborative licensing and development
arrangements are recognized as the Company fulfills its
obligations related to the various elements within the
agreements, in accordance with the contractual arrangements
with third parties and the term over which the underlying
benefit is being conferred. Revenue earned under
contractual arrangements upon the occurrence of specified
milestones is recognized as the milestones are achieved and
collection is reasonably assured.
Revenue
earned under research and development manufacturing
collaborations where the Company bears some or all of the
risk of a product manufacturing failure is recognized when
the purchaser accepts the product and there are no remaining
rights of return.
Revenue
earned under research and development collaborations where
the Company does not bear any risk of product manufacturing
failure is recognized in the period the work is
performed.
Revenue
and expenses under the contract with the United States
Government are being recorded using the
percentage-of-completion method. Contract progress is based
on costs incurred to date. Expenses under the contract are
recorded in the Company’s consolidated statement of
operations and comprehensive income (loss) as they are
incurred. Government contract revenues related to expenses
incurred under the contract are recorded in the same period
as those expenses. Expenses accrued under the contract but
not yet invoiced are recorded in the Company’s balance
sheet as accrued liabilities and accrued revenues. Equipment
purchased under the contract is recorded on the
Company’s balance sheet as deferred expense and
deferred revenue and amortized, on a straight-line basis,
over the life of the contract.
Cash
or other compensation received in advance of meeting the
revenue recognition criteria is recorded on the balance sheet
as deferred revenue. Revenue meeting recognition criteria but
not yet received or receivable is recorded on the balance
sheet as accrued revenue. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Lease, Policy [Policy Text Block] | Leases
and lease inducements
Leases
entered into are classified as either capital or operating
leases. Leases which substantially transfer all benefits and
risks of ownership of property to the Company are accounted
for as capital leases. At the time a capital lease
is entered into, an asset is recorded together with its
related long-term obligation to reflect the purchase and
financing.
All
other leases are accounted for as operating leases wherein
rental payments are expensed as incurred.
Lease
inducements represent leasehold improvement allowances and
reduced or free rent periods and are amortized on a
straight-line basis over the term of the lease and are
recorded as a reduction of rent expense |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Research, Development, and Computer Software, Policy [Policy Text Block] | Research
and development costs
Research
and development costs, including acquired in-process research
and development expenses for which there is no alternative
future use, are charged as an expense in the period in which
they are incurred. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Earnings Per Share, Policy [Policy Text Block] | Income
or loss per share
Income
or loss per share is calculated based on the weighted average
number of common shares outstanding. Diluted loss
per share does not differ from basic loss per share since the
effect of the Company’s stock options and warrants is
anti-dilutive. Diluted income per share is calculated using
the treasury stock method which uses the weighted average
number of common shares outstanding during the period and
also includes the dilutive effect of potentially issuable
common shares from outstanding, in-the-money stock options
and warrants.
The
following table sets out the computation of basic and diluted
net income (loss) per common share:
For
the year ended December 31, 2012, potential common shares of
1,085,503 were excluded from the calculation of income per
common share because their inclusion would be anti-dilutive
(December 31, 2011 –2,830,635; December 31, 2010
– 1,627,280). |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Government Grants And Refundable Intestment Tax Credits [Policy Text Block] | Government
grants and refundable investment tax credits
Government
grants and tax credits provided for current expenses is
included in the determination of income or loss for the year,
as a reduction of the expenses to which it relates.
Government grants and tax credits towards the acquisition of
property and equipment is deducted from the cost of the
related property and equipment. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Foreign Currency Transactions and Translations Policy [Policy Text Block] | Foreign
currency translation
The
functional currency of the Company is the Canadian dollar.
For the Company and its integrated subsidiaries (Protiva
Biotherapeutics Inc. and Protiva Biotherapeutics (USA),
Inc.), foreign currency monetary assets and liabilities are
translated into Canadian dollars at the rate of exchange
prevailing at the balance sheet date. Non-monetary
assets and liabilities are translated at historical exchange
rates. The previous month’s closing rate of exchange is
used to translate revenue and expense
transactions. Exchange gains and losses are
included in income or loss for the period |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Income Tax, Policy [Policy Text Block] | Deferred
income taxes
Income
taxes are accounted for using the asset and liability method
of accounting. Deferred income taxes are
recognized for the future income tax consequences
attributable to differences between the carrying values of
assets and liabilities and their respective income tax bases
and for loss carry-forwards. Deferred income tax
assets and liabilities are measured using enacted income tax
rates expected to apply to taxable income in the periods in
which temporary differences are expected to be recovered or
settled. The effect on deferred income tax assets
and liabilities of a change in tax laws or rates is included
in earnings in the period that includes the enactment
date. When realization of deferred income tax
assets does not meet the more-likely-than-not criterion for
recognition, a valuation allowance is provided. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] | Stock-based
compensation
The
Company grants stock options to employees and directors
pursuant to a share incentive plan described in note
6. Compensation expense is recorded for issued
stock options using the fair value method with a
corresponding increase in additional paid-in capital. Any
consideration received on the exercise of stock options is
credited to share capital.
The
fair value of stock options is typically measured at the
grant date and amortized on a straight-line basis over the
vesting period |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Warrants [Policy Text Block] | Warrants
The
Company accounts for the warrants under the authoritative
guidance on accounting for derivative financial instruments
indexed to, and potentially settled in, a company’s own
stock, on the understanding that in compliance with
applicable securities laws, the registered warrants require
the issuance of registered securities upon exercise and do
not sufficiently preclude an implied right to net cash
settlement. The Company classifies warrants in its
consolidated balance sheet as a liability which is revalued
at each balance sheet date subsequent to the initial
issuance. The Company uses the Black-Scholes pricing model to
value the warrants. Determining the appropriate fair-value
model and calculating the fair value of registered warrants
requires considerable judgment. A small change in the
estimates used may cause a relatively large change in the
estimated valuation. The estimated volatility of the
Company’s common stock at the date of issuance, and at
each subsequent reporting period, is based upon observations
of warrants in the market with similar characteristics and
expected remaining lives. The risk-free interest rate is
based on the zero-coupon rate for bonds with a maturity
similar to the expected remaining life of the warrants at the
valuation date. The expected life of the warrants is assumed
to be equivalent to their remaining contractual term. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Segment Reporting, Policy [Policy Text Block] | Segment
information
The
Company operates in a single reporting segment, the research
and development of RNA interference
therapeutics. Substantially all of the
Company’s revenues to date were earned from customers
or collaborators based in the United States. Substantially
all of the Company’s premises, property and equipment
is located in Canada. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| New Accounting Pronouncements, Policy [Policy Text Block] | Recent
accounting pronouncements
From
time to time, new accounting pronouncements are issued by the
Financial Accounting Standards Board (FASB) or other standard
setting bodies that are adopted by the Company as of the
specified effective date. Unless otherwise discussed, we
believe that the impact of recently issued standards that are
not yet effective will not have a material impact on our
financial position or results of operations upon
adoption.
In
December 2011, the FASB issued ASU 2011-11, Balance Sheet
(Topic 210): Disclosures about Offsetting Assets and
Liabilities. This newly issued accounting standard
requires an entity to disclose both gross and net information
about instruments and transactions eligible for offset in the
balance sheet as well as instruments and transactions
executed under a master netting or similar arrangement and
was issued to enable users of financial statements to
understand the effects or potential effects of those
arrangements on its balance sheet. This ASU is required to be
applied retrospectively and is effective for fiscal years,
and interim periods within those years, beginning on or after
January 1, 2013. As this accounting standard only
requires enhanced disclosure, the adoption of this standard
is not expected to have an impact on the Company’s
financial position or statement of operations.
In
June 2011, the FASB issued ASU No. 2011-05, Comprehensive
Income (Topic 220): Presentation of Comprehensive
Income. This newly issued accounting standard
(1) eliminates the option to present the components of
other comprehensive income as part of the statement of
changes in stockholders’ equity; (2) requires the
consecutive presentation of the statement of net income and
other comprehensive income; and (3) requires an entity
to present reclassification adjustments on the face of the
financial statements from other comprehensive income to net
income. The amendments in this ASU do not change the items
that must be reported in other comprehensive income or when
an item of other comprehensive income must be reclassified to
net income nor do the amendments affect how earnings per
share is calculated or presented. In December 2011, the FASB
issued ASU No. 2011-12, Deferral of the
Effective Date for Amendments to the Presentation of
Reclassifications of Items Out of Accumulated Other
Comprehensive Income in Accounting Standards Update
No. 2011-05, which defers the requirement within
ASU 2011-05 to present on the face of the financial
statements the effects of reclassifications out of
accumulated other comprehensive income on the components of
net income and other comprehensive income for all periods
presented. During the deferral, entities should continue to
report reclassifications out of accumulated other
comprehensive income consistent with the presentation
requirements in effect prior to the issuance of ASU 2011-05.
These ASUs are required to be applied retrospectively and are
effective for fiscal years, and interim periods within those
years, beginning after December 15, 2011, which for the
Company means January 1, 2012. As these accounting
standards do not change the items that must be reported in
other comprehensive income or when an item of other
comprehensive income must be reclassified to net income, the
adoption of these standards did not have an impact on the
Company’s financial position or results of
operations.
In
February 2013, the FASB issued amendments to the accounting
guidance for presentation of comprehensive income to improve
the reporting of reclassifications out of accumulated other
comprehensive income. The amendments do not change the
current requirements for reporting net income or other
comprehensive income, but do require an entity to provide
information about the amounts reclassified out of accumulated
other comprehensive income by component. In addition, an
entity is required to present, either on the face of the
statement where the net income is presented or in the notes,
significant amounts reclassified out of accumulated other
comprehensive income by the respective line items of net
income but only if the amount reclassified is required under
GAAP to be reclassified to net income in its entirety in the
same reporting period. For other amounts that are not
required under GAAP to be reclassified in their entirety to
net income, an entity is required to cross-reference to other
disclosures required under GAAP that provide additional
detail about these amounts. For public companies, these
amendments are effective prospectively for reporting periods
beginning after December 15, 2012. We do not believe the
adoption of this guidance will have a material impact on our
consolidated financial statements.
In
May 2011, the FASB issued ASU No. 2011-04, Fair Value
Measurement (Topic 820): Amendments to Achieve Common Fair
Value Measurement and Disclosure Requirements in
U.S. GAAP and IFRSs. This newly issued accounting
standard clarifies the application of certain existing fair
value measurement guidance and expands the disclosures for
fair value measurements that are estimated using significant
unobservable (Level 3) inputs. This ASU is
effective on a prospective basis for annual and interim
reporting periods beginning on or after December 15,
2011, which for the Company means January 1, 2012. The
adoption of this standard did not have a material impact on
the Company’s financial position or results of
operations. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). No definition available.
|
| X | ||||||||||
|
- Definition
Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Disclosure of accounting policy for fair value measurements, which may include, but is not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Disclosure of accounting policy for major classes of inventories, bases of stating inventories (for example, lower of cost or market), methods by which amounts are added and removed from inventory classes (for example, FIFO, LIFO, or average cost), loss recognition on impairment of inventories, and situations in which inventories are stated above cost. If inventory is carried at cost, this disclosure includes the nature of the cost elements included in inventory. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Disclosure of accounting policy for leasing arrangements (both lessor and lessee). This disclosure may address (1) lease classification (that is, operating versus capital), (2) how the term of a lease is determined (for example, the circumstances in which a renewal option is considered part of the lease term), (3) how rental revenue or expense is recognized for a lease that contains rent escalations, (4) an entity's accounting treatment for deferred rent, including that which arises from lease incentives, rent abatements, rent holidays, or tenant allowances (5) an entity's accounting treatment for contingent rental payments and (6) an entity's policy for reviewing, at least annually, the residual values of sales-type and direct-finance leases. The disclosure also may indicate how the entity accounts for its capital leases, leveraged leases or sale-leaseback transactions. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Disclosure of the adoption of new accounting pronouncements that may impact the entity's financial reporting. No definition available.
|
| X | ||||||||||
|
- Definition
Disclosure of accounting policy for property, plant and equipment which may include the basis of such assets, depreciation methods used and estimated useful lives, the entity's capitalization policy, including its accounting treatment for costs incurred for repairs and maintenance activities, whether such asset balances include capitalized interest and the method by which such is calculated, how disposals of such assets are accounted for and how impairment of such assets is assessed and recognized. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Disclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Disclosure of accounting policy for segment reporting. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 2 - Significant accounting policies (Tables)
|
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2012
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fair Value, Assets Measured on Recurring Basis [Table Text Block] |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Changes In Fair Value Of Warrants [Table Text Block] |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Property, Plant and Equipment, Estimated Useful Lives |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Tabular disclosure of an entity's basic and diluted earnings per share calculations. No definition available.
|
|
Note 3 - Collaborations, contracts and licensing agreements (Tables)
|
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2012
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table Text Block] |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Deferred Revenue, by Arrangement, Disclosure [Table Text Block] |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
Tabular disclosure of the type of arrangements and the corresponding amounts that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Tabular disclosure of contractual arrangements that involve two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity. Additionally, the element may include all other transactions of the entity categorized collectively, if such comparison of collaborative arrangements as a component of all transactions of the entity is desired. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 4 - Property and equipment (Tables)
|
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2012
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Property, Plant and Equipment [Table Text Block] |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
Tabular disclosure of the useful life and salvage value of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 6 - Share Capital (Tables)
|
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2012
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule Of Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range [Table Text Block] |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Nonvested Share Activity [Table Text Block] |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block] |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block] |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Tabular disclosure of the changes in outstanding nonvested shares. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Tabular disclosure of the weighted-average grant-date fair value of equity options or other equity instruments granted during the year. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Tabular disclosure of the number of fully vested share options (or share units) and share options expected to vest at the date of the latest statement of financial position, weighted-average exercise price (or conversion ratio), aggregate intrinsic value (except for nonpublic entities), and weighted-average remaining contractual term for both options (or share units) currently outstanding and options (or share units) exercisable (or convertible). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 8 - Income taxes - outstanding (Tables)
|
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2012
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Deferred Tax Assets and Liabilities [Table Text Block] |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 9 - Contingencies and commitments (Tables)
|
12 Months Ended | |||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2012
|
||||||||||||||||||||||||||
| Operating Leases of Lessee Disclosure [Table Text Block] |
|
|||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
Tabular disclosure of a lessee's leasing arrangements including: (1) the basis on which contingent rental payments are determined, (2) the existence and terms of renewal or purchase options and escalation clauses, (3) restrictions imposed by lease arrangements, such as those concerning dividends, additional debt, and further leasing, (4) rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions. Disclosure may also include the specific period used to amortize material leasehold improvements made at the inception of the lease or during the lease term. Additionally, for operating leases having initial or remaining noncancelable lease terms in excess of one year: (a) future minimum rental payments required as of the date of the latest balance sheet presented, in the aggregate and for each of the five succeeding fiscal years, (b) the total of minimum rentals to be received in the future under noncancelable subleases as of the date of the latest balance sheet presented, and (c) for all operating leases, rental expense for each period for which an income statement is presented, with separate amounts for minimum rentals, contingent rentals, and sublease rentals. Rental payments under leases with terms of a month or less that were not renewed need not be included. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 10 - Concentrations of business risk (Tables)
|
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2012
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cash, Cash Equivalents, and Marketable Securities [Text Block] |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Intercompany Foreign Currency Balances [Table Text Block] |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss). No definition available.
|
| X | ||||||||||
|
- Definition
Tabular disclosure of long-term intercompany foreign balances, including related intercompany entity, underlying foreign currencies and amounts of intercompany foreign currency transactions that are of a long-term investment nature (that is settlement is not planned or anticipated in the foreseeable future), as of the balance sheet date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 11 - Supplementary information (Tables)
|
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2012
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses. No definition available.
|
|
Note 2 - Significant accounting policies (Detail)
|
12 Months Ended | ||
|---|---|---|---|
|
Dec. 31, 2012
|
Dec. 31, 2011
|
Dec. 31, 2010
|
|
| Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in Shares) | 1,085,503 | 2,830,635 | 1,627,280 |
| X | ||||||||||
|
- Definition
Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 2 - Significant accounting policies (Detail) - Assets and Liabilities that are Measure at Fair Value (CAD)
|
Dec. 31, 2012
|
Dec. 31, 2011
|
|---|---|---|
| Cash | 44,148,562 | 1,556,253 |
| Guaranteed Investment Certificates | 2,636,956 | 7,627,881 |
| Total | 46,785,518 | 9,184,134 |
| Warrants | 3,994,449 | 205,044 |
|
Fair Value, Inputs, Level 1 [Member]
|
||
| Cash | 44,148,562 | 1,556,253 |
| Guaranteed Investment Certificates | 2,636,956 | 7,627,881 |
| Total | 46,785,518 | 9,184,134 |
|
Fair Value, Inputs, Level 3 [Member]
|
||
| Warrants | 3,994,449 | 205,044 |
| X | ||||||||||
|
- Definition
This element represents the aggregate of the assets reported on the balance sheet at period end measured at fair value by the entity. This element is intended to be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
This element represents the portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. This item includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Company may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
This element represents the portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. This item represents investment securities as of the balance sheet date which may include marketable securities, derivative financial instruments, and investments accounted for under the equity method. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. This item represents warrants not settleable in cash classified as equity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 2 - Significant accounting policies (Detail) - Changes in fair value of the Company’s warrants (CAD)
|
12 Months Ended | |
|---|---|---|
|
Dec. 31, 2012
|
Dec. 31, 2011
|
|
| Liability at beginning of the period | 205,044 | |
| Opening liability of warrants issued in the period | 850,358 | 742,809 |
| Increase (decrease) in value of warrants | 3,819,170 | (572,769) |
| Liability at end of the period | 3,994,449 | 205,044 |
|
Change In Fair Value [Member]
|
||
| Liability at beginning of the period | 205,044 | |
| Opening liability of warrants issued in the period | 850,358 | 777,813 |
| Fair value of warrants exercised in the period | (880,123) | |
| Increase (decrease) in value of warrants | 3,819,170 | (572,769) |
| Liability at end of the period | 3,994,449 | 205,044 |
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
For each line item in the statement of financial position, the amounts of gains and losses from fair value changes included in earnings. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. This item represents warrants not settleable in cash classified as equity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 2 - Significant accounting policies (Detail) - Estimated useful lives
|
12 Months Ended |
|---|---|
|
Dec. 31, 2012
|
|
|
Laboratory Equipment [Member] | Minimum [Member]
|
|
| Useful Lives | 5 years |
|
Computer Equipment [Member] | Minimum [Member]
|
|
| Useful Lives | 2 years |
|
Computer Equipment [Member] | Maximum [Member]
|
|
| Useful Lives | 5 years |
|
Furniture and Fixtures [Member] | Minimum [Member]
|
|
| Useful Lives | 5 years |
| X | ||||||||||
|
- Definition
Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment. No definition available.
|
|
Note 2 - Significant accounting policies (Detail) - Computation of basic and diluted net income (loss) per common share (CAD)
|
12 Months Ended | ||
|---|---|---|---|
|
Dec. 31, 2012
|
Dec. 31, 2011
|
Dec. 31, 2010
|
|
| Net income (loss) (in Dollars) | 29,793,048 | (9,936,926) | (12,415,480) |
| Weighted average number of common shares | 13,727,925 | 11,318,766 | 10,332,941 |
| Diluted weighted average number of common shares | 14,320,814 | 11,318,766 | 10,332,941 |
| Basic income (loss) per common share (in Dollars per share) | 2.17 | (0.88) | (1.20) |
| Diluted income (loss) per common share (in Dollars per share) | 2.08 | (0.88) | (1.20) |
|
Warrant [Member]
|
|||
| Dilutive Securities (in Dollars) | 177,374 | ||
|
Stock Options [Member]
|
|||
| Dilutive Securities (in Dollars) | 415,515 | ||
| X | ||||||||||
|
- Definition
Includes adjustments resulting from the assumption that dilutive convertible securities were converted, options or warrants were exercised, or that other shares were issued upon the satisfaction of certain conditions. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 3 - Collaborations, contracts and licensing agreements (Detail)
|
0 Months Ended | 1 Months Ended | 2 Months Ended | 12 Months Ended | 12 Months Ended | 12 Months Ended | 1 Months Ended | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 10, 2012
USD ($)
|
Dec. 10, 2012
CAD
|
Jun. 30, 2012
USD ($)
|
Jun. 30, 2012
CAD
|
Sep. 20, 2010
USD ($)
|
Sep. 20, 2010
CAD
|
Dec. 31, 2012
USD ($)
|
Dec. 31, 2012
CAD
|
Dec. 31, 2012
USD ($)
|
Dec. 31, 2012
CAD
|
Dec. 31, 2011
USD ($)
|
Dec. 31, 2011
CAD
|
Dec. 31, 2010
USD ($)
|
Dec. 31, 2010
CAD
|
Jul. 14, 2010
USD ($)
|
May 11, 2009
USD ($)
|
Jun. 20, 2006
USD ($)
|
Dec. 31, 2012
Talon Therapeutics [Member]
USD ($)
|
Dec. 31, 2012
Merck [Member]
Maximum [Member]
Acquired Intellectual Property [Member]
USD ($)
|
Dec. 31, 2012
Merck [Member]
Maximum [Member]
Acquired Intellectual Propert First One [Member]
USD ($)
|
Dec. 31, 2012
Maximum [Member]
USD ($)
|
Jul. 14, 2010
Contract Extension [Member]
USD ($)
|
Dec. 31, 2012
Cross License Agreement [Member]
USD ($)
|
Dec. 31, 2012
Alnylam License Agreement [Member]
CAD
|
Dec. 31, 2012
Milestone Payment [Member]
CAD
|
Dec. 31, 2011
Provision Of Staff [Member]
CAD
|
Nov. 26, 2012
Termination Of Manufacturing Agreement [Member]
USD ($)
|
Nov. 26, 2012
Termination Of Prior License Agreements [Member]
USD ($)
|
|
| Potential Contract Funding Amount (in Dollars) | $ 34,700,000 | $ 8,800,000 | $ 18,000,000 | $ 17,000,000 | $ 15,000,000 | $ 140,000,000 | 11,200,000 | |||||||||||||||||||||
| Licenses Revenue (in Dollars) | 1,000,000 | 1,018,100 | 2,010,100 | 524,100 | 514,129 | |||||||||||||||||||||||
| Licenses Revenue | 1,000,000 | 1,018,100 | 2,010,100 | 524,100 | 514,129 | |||||||||||||||||||||||
| License Costs (in Dollars) | 300,000 | 298,080 | 8,500,000 | 1,492,350 | 100,000 | 97,940 | 1,300,000 | 1,500,000 | ||||||||||||||||||||
| License Costs | 300,000 | 298,080 | 8,500,000 | 1,492,350 | 100,000 | 97,940 | 1,300,000 | 1,500,000 | ||||||||||||||||||||
| License amendment payment (in Dollars) | 5,750,000 | 5,916,750 | 65,000,000 | 5,916,750 | 65,039,000 | 30,000,000 | 35,000,000 | |||||||||||||||||||||
| License amendment payment | 5,750,000 | 5,916,750 | 65,000,000 | 5,916,750 | 65,039,000 | 30,000,000 | 35,000,000 | |||||||||||||||||||||
| Legal Fees (in Dollars) | 18,737,966 | 18,618,043 | 18,618,043 | |||||||||||||||||||||||||
| Legal Fees | 18,737,966 | 18,618,043 | 18,618,043 | |||||||||||||||||||||||||
| Deferred Revenue (in Dollars) | 3,000,000 | 3,233,400 | ||||||||||||||||||||||||||
| Deferred Revenue | 3,000,000 | 3,233,400 | ||||||||||||||||||||||||||
| Commitments and Contingencies | 22,835,476 | |||||||||||||||||||||||||||
| Gains (Losses) on Extinguishment of Debt (in Dollars) | 5,750,000 | (5,916,750) | ||||||||||||||||||||||||||
| Gains (Losses) on Extinguishment of Debt | 5,750,000 | (5,916,750) | ||||||||||||||||||||||||||
| Contracts Revenue (in Dollars) | 1,000,000 | 12,097,378 | 16,122,843 | 14,923,860 | 992,000 | |||||||||||||||||||||||
| Contracts Revenue | $ 1,000,000 | 12,097,378 | 16,122,843 | 14,923,860 | 992,000 | |||||||||||||||||||||||
| X | ||||||||||
|
- Definition
Other license revenue derived from amendments to contractual license agreements. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Revenue earned during the period arising from products sold or services provided under the terms of a contract, not elsewhere specified in the taxonomy. May include government contracts, construction contracts, and any other contract related to a particular project or product. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Costs incurred and are directly related to generating license revenue. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 3 - Collaborations, contracts and licensing agreements (Detail) - Revenue recognized under collaborations, contracts and licensing agreements
|
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2012
USD ($)
|
Dec. 31, 2012
CAD
|
Dec. 31, 2011
CAD
|
Dec. 31, 2010
CAD
|
Dec. 31, 2012
Alnylam [Member]
CAD
|
Dec. 31, 2011
Alnylam [Member]
CAD
|
Dec. 31, 2010
Alnylam [Member]
CAD
|
Dec. 31, 2012
Talon Therapeutics [Member]
CAD
|
Dec. 31, 2011
Talon Therapeutics [Member]
CAD
|
Dec. 31, 2010
Talon Therapeutics [Member]
CAD
|
Dec. 31, 2012
Total [Member]
CAD
|
Dec. 31, 2011
Total [Member]
CAD
|
Dec. 31, 2010
Total [Member]
CAD
|
Dec. 31, 2012
US Government [Member]
CAD
|
Dec. 31, 2011
US Government [Member]
CAD
|
Dec. 31, 2010
US Government [Member]
CAD
|
Dec. 31, 2012
Alnylam [Member]
CAD
|
Dec. 31, 2011
Alnylam [Member]
CAD
|
Dec. 31, 2010
Alnylam [Member]
CAD
|
Dec. 31, 2012
BMS [Member]
CAD
|
Dec. 31, 2011
BMS [Member]
CAD
|
Dec. 31, 2010
BMS [Member]
CAD
|
Dec. 31, 2012
Roche [Member]
CAD
|
Dec. 31, 2011
Roche [Member]
CAD
|
Dec. 31, 2010
Roche [Member]
CAD
|
Dec. 31, 2012
Other RNAi Collaborators [Member]
CAD
|
Dec. 31, 2011
Other RNAi Collaborators [Member]
CAD
|
Dec. 31, 2010
Other RNAi Collaborators [Member]
CAD
|
Dec. 31, 2012
Total [Member]
CAD
|
Dec. 31, 2011
Total [Member]
CAD
|
Dec. 31, 2010
Total [Member]
CAD
|
||||||||||||||||||||||||||||||||||
| Revenue recognized under collaborations, contracts and licensing agreements | $ 1,000,000 | 12,097,378 | 16,122,843 | 14,923,860 | 1,018,100 | [1] | 524,100 | [1] | 514,129 | [1] | 992,000 | [2] | [2] | 5,916,750 | [2] | 2,010,100 | 524,100 | 6,430,879 | 11,528,660 | [3] | 11,432,163 | [3] | 3,560,711 | [3] | 9,713 | [1] | 4,142,796 | [1] | 6,258,535 | [1] | 439,995 | [4] | 432,106 | [4] | 227,995 | [4] | [5] | 40,232 | [5] | 4,499,689 | [5] | 119,010 | [6] | 75,546 | [6] | 376,930 | [6] | 12,097,378 | 16,122,843 | 14,923,860 | ||||||||||||||
| Total revenue | 14,107,478 | 16,646,943 | 21,354,739 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
Revenue earned during the period arising from products sold or services provided under the terms of a contract, not elsewhere specified in the taxonomy. May include government contracts, construction contracts, and any other contract related to a particular project or product. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Aggregate revenue recognized during the period (derived from goods sold, services rendered, insurance premiums, or other activities that constitute an entity's earning process). For financial services companies, also includes investment and interest income, and sales and trading gains. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 3 - Collaborations, contracts and licensing agreements (Detail) - Deferred collaborations and contracts revenue (CAD)
|
Dec. 31, 2012
|
Dec. 31, 2011
|
||||||
|---|---|---|---|---|---|---|---|---|
| Deferred Revenue Current Portion | 3,127,629 | 2,807,898 | ||||||
| Deferred Revenue Long-term Portion | 718,779 | 1,690,529 | ||||||
|
US Government [Member]
|
||||||||
| Deferred Revenue Current Portion | 1,381,922 | [1] | 1,593,946 | [1] | ||||
|
BMS [Member]
|
||||||||
| Deferred Revenue Current Portion | 1,745,707 | [2] | 1,213,952 | [2] | ||||
| Deferred Revenue Long-term Portion | 718,779 | [2] | 1,690,529 | [2] | ||||
|
Total [Member]
|
||||||||
| Deferred Revenue Current Portion | 3,127,629 | 2,807,898 | ||||||
| Deferred Revenue Long-term Portion | 3,846,408 | 4,498,427 | ||||||
|
||||||||
| X | ||||||||||
|
- Definition
The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 4 - Property and equipment (Detail) (CAD)
|
Dec. 31, 2012
|
Dec. 31, 2011
|
|---|---|---|
| Property, Plant and Equipment, Net | 1,344,872 | 2,197,579 |
| Property, Plant and Equipment, Gross | 13,121,268 | 18,684,491 |
|
Property Not In Use [Member]
|
||
| Property, Plant and Equipment, Net | 0 | |
| Property, Plant and Equipment, Gross | 5,574,219 |
| X | ||||||||||
|
- Definition
Gross amount of long-lived physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount, net of accumulated depreciation, depletion and amortization, of long-lived physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 4 - Property and equipment (Detail) - Property and equipment summary (CAD)
|
Dec. 31, 2012
|
Dec. 31, 2011
|
|---|---|---|
| Cost | 13,121,268 | 18,684,491 |
| Accumulated depreciation and impairment | (11,776,396) | (16,486,912) |
| Net book value | 1,344,872 | 2,197,579 |
|
Laboratory Equipment [Member]
|
||
| Cost | 5,110,910 | 7,688,286 |
| Accumulated depreciation and impairment | (4,763,611) | (6,984,194) |
| Net book value | 347,299 | 704,092 |
|
Leasehold Improvements [Member]
|
||
| Cost | 5,948,003 | 7,212,104 |
| Accumulated depreciation and impairment | (5,016,316) | (5,976,916) |
| Net book value | 931,687 | 1,235,188 |
|
Computer And Office Equipment [Member]
|
||
| Cost | 1,641,223 | 3,120,072 |
| Accumulated depreciation and impairment | (1,577,244) | (2,869,622) |
| Net book value | 63,979 | 250,450 |
|
Furniture and Fixtures [Member]
|
||
| Cost | 421,132 | 664,029 |
| Accumulated depreciation and impairment | (419,225) | (656,180) |
| Net book value | 1,907 | 7,849 |
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
Gross amount of long-lived physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount, net of accumulated depreciation, depletion and amortization, of long-lived physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 5 - Borrowing Facility (Detail)
|
1 Months Ended | 0 Months Ended | 12 Months Ended | 12 Months Ended | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Feb. 29, 2012
CAD
|
Jun. 16, 2011
CAD
|
Dec. 31, 2012
CAD
|
Dec. 31, 2011
CAD
|
Dec. 31, 2012
USD ($)
|
Dec. 21, 2012
|
Dec. 31, 2011
USD ($)
|
Dec. 21, 2011
USD ($)
|
Dec. 21, 2011
CAD
|
Dec. 31, 2012
Black-Scholes Aggregate Value [Member]
CAD
|
Dec. 31, 2011
Black-Scholes Aggregate Value [Member]
CAD
|
Dec. 31, 2012
Silicon Valley Bank [Member]
|
Dec. 31, 2012
Silicon Valley Bank [Member]
|
Dec. 31, 2011
Silicon Valley Bank [Member]
|
Dec. 31, 2012
General And Administrative Expenses [Member]
CAD
|
Dec. 31, 2011
General And Administrative Expenses [Member]
CAD
|
|
| Line of Credit Facility, Maximum Borrowing Capacity (in Dollars and Dollars) | 3,051,000 | $ 3,000,000 | $ 3,000,000 | $ 3,000,000 | 3,051,000 | |||||||||||
| Debt Instrument, Interest Rate, Stated Percentage | 8.00% | |||||||||||||||
| Issuance Of Common Share Purchase Warrants (in Shares) | 54,545 | |||||||||||||||
| Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per Item) | 924,302 | 3.00 | 3.25 | 1.65 | ||||||||||||
| Warrants and Rights Outstanding (in Dollars) | 850,358 | 742,809 | 3,994,449 | 205,044 | 35,004 | 35,004 | ||||||||||
| Fair Value Assumptions, Risk Free Interest Rate | 1.44% | 2.19% | 1.24% | 1.51% | 1.48% | |||||||||||
| Fair Value Assumptions, Expected Volatility Rate | 40.00% | 40.00% | 40.00% | 40.00% | ||||||||||||
| Fair Value Assumptions, Expected Dividend Rate | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||||||||
| Fair Value Assumptions, Expected Term | 5 years | 5 years | 7 years | 6 years 357 days | ||||||||||||
| Stock Issued During Period, Shares, Other (in Shares) | 54,545 | |||||||||||||||
| Loan Processing Fee (in Dollars) | 70,095 | |||||||||||||||
| (in Dollars) | 850,358 | 742,809 | 35,004 | |||||||||||||
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
The exercise price of each class of warrants or rights outstanding. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Interest rate stated in the contractual debt agreement. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Risk-free interest rate assumption used in valuing an instrument. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Expenses paid for obtaining loans which includes expenses such as application and origination fees. No definition available.
|
| X | ||||||||||
|
- Definition
Number of shares of stock issued during the period that is attributable to transactions involving issuance of stock not separately disclosed. No definition available.
|
| X | ||||||||||
|
- Definition
Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Exercise price of the option. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
The exercise price of each class of warrants or rights outstanding. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The specified number of securities that each class of warrants or rights outstanding give the holder the right but not the obligation to purchase from the issuer at a specific price, on or before a certain date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Aggregate number of common shares reserved for future issuance. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
As of the balance sheet date, the aggregate unrecognized cost of equity-based awards made to employees under equity-based compensation awards that have yet to vest. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Risk-free interest rate assumption used in valuing an instrument. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The cash inflow from the additional capital contribution to the entity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The cash inflow associated with the amount received from holders exercising their stock warrants. No definition available.
|
| X | ||||||||||
|
- Definition
Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The total accumulated difference between fair values of underlying shares on dates of exercise and exercise price on options which were exercised (or share units converted) into shares during the reporting period under the plan. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of options outstanding. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are outstanding as of the balance sheet date, including vested options. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock. No definition available.
|
| X | ||||||||||
|
- Definition
Price of a single share of a number of saleable stocks of a company. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Number of shares issued during the period as a result of the conversion of convertible securities. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Number of new stock issued during the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Reduction in the number of shares during the period as a result of a reverse stock split. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Class Of Warrant Or Right Price Of Warrants Or Rights Contractual Term No definition available.
|
| X | ||||||||||
|
- Definition
Class Of Warrant Or Right Price Of Warrants Or Rights Intrinsic Value No definition available.
|
| X | ||||||||||
|
- Definition
Class Of Warrant Or Right Range Of Exercise Price Of Warrants Or Rights Maximum No definition available.
|
| X | ||||||||||
|
- Definition
Class Of Warrant Or Right Range Of Exercise Price Of Warrants Or Rights Minimum No definition available.
|
| X | ||||||||||
|
- Definition
The exercise price of each class of warrants or rights outstanding. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The specified number of securities that each class of warrants or rights outstanding give the holder the right but not the obligation to purchase from the issuer at a specific price, on or before a certain date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 6 - Share Capital (Detail) - Black-Scholes Option-Pricing Assumptions (CAD)
|
1 Months Ended | 0 Months Ended | 12 Months Ended | |
|---|---|---|---|---|
|
Feb. 29, 2012
|
Jun. 16, 2011
|
Dec. 31, 2012
|
Dec. 31, 2011
|
|
| Dividend yield | 0.00% | 0.00% | 0.00% | 0.00% |
| Expected volatility | 40.00% | 40.00% | 40.00% | 40.00% |
| Risk-free interest rate | 1.44% | 2.19% | 1.24% | 1.51% |
| Expected average term (years) | 5 years | 5 years | 7 years | 6 years 357 days |
| Fair value of warrants outstanding (in Dollars per share) | 2.43 | 0.22 | ||
| Aggregate fair value of warrants outstanding (in Dollars) | 850,358 | 742,809 | 3,994,449 | 205,044 |
| X | ||||||||||
|
- Definition
Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Risk-free interest rate assumption used in valuing an instrument. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 6 - Share Capital (Detail) - Stock Option Activity (CAD)
|
Dec. 31, 2012
|
Dec. 31, 2010
|
Dec. 31, 2009
|
Dec. 31, 2012
Granted [Member]
|
Dec. 31, 2011
Granted [Member]
|
Dec. 31, 2010
Granted [Member]
|
Dec. 31, 2012
Exercised [Member]
|
Dec. 31, 2011
Exercised [Member]
|
Dec. 31, 2010
Exercised [Member]
|
Dec. 31, 2012
Forfeited, Cancelled or Expired [Member]
|
Dec. 31, 2011
Forfeited, Cancelled or Expired [Member]
|
Dec. 31, 2010
Forfeited, Cancelled or Expired [Member]
|
Dec. 31, 2012
Total [Member]
|
Dec. 31, 2011
Total [Member]
|
Dec. 31, 2010
Total [Member]
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of optioned common shares | 1,970,145 | 865,628 | 326,300 | 403,100 | 275,225 | (28,417) | (1,667) | (9,548) | (62,355) | (71,547) | (47,873) | 1,648,846 | 1,413,318 | 1,083,432 | |
| Weighted average exercise price (in Dollars per share) | 10.10 | 4.16 | 2.14 | 4.40 | 2.34 | 1.50 | 3.63 | 21.27 | 27.42 | 27.38 | 4.54 | 5.32 | 7.95 | ||
| Aggregate intrinsic value (in Dollars) | 450,330 | 175,905 | 705,885 | 81,545 | 1,330 | 29,320 | 2,299,512 | 1,800 | 756,628 |
| X | ||||||||||
|
- Definition
Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of options outstanding. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are outstanding as of the balance sheet date, including vested options. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 6 - Share Capital (Detail) - Stock Options Outstanding (CAD)
|
12 Months Ended | 12 Months Ended | 12 Months Ended | 12 Months Ended | 12 Months Ended | 12 Months Ended | 12 Months Ended | 12 Months Ended | 12 Months Ended | 12 Months Ended | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2009
|
Dec. 31, 2012
Exercise Price 1.50 To 1.90 [Member]
Outstanding [Member]
|
Dec. 31, 2012
Exercise Price 1.50 To 1.90 [Member]
Exercisable [Member]
|
Dec. 31, 2012
Exercise Price 1.50 To 1.90 [Member]
|
Dec. 31, 2012
Exercise Price 2.10 To 2.60 [Member]
Outstanding [Member]
|
Dec. 31, 2012
Exercise Price 2.10 To 2.60 [Member]
Exercisable [Member]
|
Dec. 31, 2012
Exercise Price 2.10 To 2.60 [Member]
|
Dec. 31, 2012
Exercise Price 3.00 To 3.10 [Member]
Outstanding [Member]
|
Dec. 31, 2012
Exercise Price 3.00 To 3.10 [Member]
Exercisable [Member]
|
Dec. 31, 2012
Exercise Price 3.00 To 3.10 [Member]
|
Dec. 31, 2012
Exercise Price 3.73 To 3.85 [Member]
Outstanding [Member]
|
Dec. 31, 2012
Exercise Price 3.73 To 3.85 [Member]
Exercisable [Member]
|
Dec. 31, 2012
Exercise Price 3.73 To 3.85 [Member]
|
Dec. 31, 2012
Exercise Price 4.60 To 5.15 [Member]
Outstanding [Member]
|
Dec. 31, 2012
Exercise Price 4.60 To 5.15 [Member]
Exercisable [Member]
|
Dec. 31, 2012
Exercise Price 4.60 To 5.15 [Member]
|
Dec. 31, 2012
Exercise Price 5.35 To 5.60 [Member]
Outstanding [Member]
|
Dec. 31, 2012
Exercise Price 5.35 To 5.60 [Member]
Exercisable [Member]
|
Dec. 31, 2012
Exercise Price 5.35 To 5.60 [Member]
|
Dec. 31, 2012
Exercise Price 5.90 To 11.60 [Member]
Outstanding [Member]
|
Dec. 31, 2012
Exercise Price 5.90 To 11.60 [Member]
Exercisable [Member]
|
Dec. 31, 2012
Exercise Price 5.90 To 11.60 [Member]
|
Dec. 31, 2012
Exercise Price 49.20 To 69.00 [Member]
Outstanding [Member]
|
Dec. 31, 2012
Exercise Price 49.20 To 69.00 [Member]
Exercisable [Member]
|
Dec. 31, 2012
Exercise Price 49.20 To 69.00 [Member]
|
Dec. 31, 2012
Exercise Price 1.50 To 69.00 [Member]
Outstanding [Member]
|
Dec. 31, 2012
Exercise Price 1.50 To 69.00 [Member]
Exercisable [Member]
|
Dec. 31, 2012
Exercise Price 1.50 To 69.00 [Member]
|
|
| Range of Exercise prices - Low | 1.50 | 2.10 | 3.00 | 3.73 | 4.60 | 5.35 | 5.90 | 49.20 | 1.50 | |||||||||||||||||||
| Range of Exercise prices - High | 1.90 | 2.60 | 3.10 | 3.85 | 5.15 | 5.60 | 11.60 | 69.00 | 69.00 | |||||||||||||||||||
| Number of options outstanding (in Shares) | 296,450 | 316,000 | 129,525 | 176,550 | 321,565 | 270,041 | 117,465 | 21,250 | 1,648,846 | |||||||||||||||||||
| Weighted average remaining contractual life (years) | 7 years 219 days | 8 years 292 days | 3 years 73 days | 7 years 36 days | 8 years 328 days | 4 years 292 days | 4 years 109 days | 328 days | 6 years 328 days | |||||||||||||||||||
| Weighted average exercise price | 10.10 | 1.71 | 2.30 | 3.03 | 3.85 | 5.00 | 5.56 | 7.08 | 58.00 | 4.54 | ||||||||||||||||||
| Number of options exercisable (in Shares) | 232,950 | 241,375 | 129,525 | 142,688 | 164,924 | 270,040 | 112,403 | 21,250 | 1,315,155 | |||||||||||||||||||
| Weighted average exercise price | 1.71 | 2.37 | 3.03 | 3.85 | 4.88 | 5.56 | 7.03 | 58.00 | 4.75 | |||||||||||||||||||
| X | ||||||||||
|
- Definition
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 6 - Share Capital (Detail) - Non-Vested Stock Option Activity (CAD)
|
12 Months Ended | |
|---|---|---|
|
Dec. 31, 2012
|
Dec. 30, 2011
|
|
| Non-vested at December 31, 2011 | 398,094 | |
| Non-vested at December 31, 2011 (in Dollars per share) | 2.51 | |
| Options granted | 326,300 | |
| Options granted (in Dollars per share) | 4.16 | |
| Options vested | (372,128) | |
| Options vested (in Dollars per share) | 2.88 | |
| Non-vested options forfeited | (18,575) | |
| Non-vested options forfeited (in Dollars per share) | 2.72 | |
| Non-vested at December 31, 2012 | 333,691 | 398,094 |
| Non-vested at December 31, 2012 (in Dollars per share) | 3.38 | 2.51 |
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Gross number of share options (or share units) granted during the period. No definition available.
|
| X | ||||||||||
|
- Definition
As of the balance sheet date, the number of shares into which fully vested and expected to vest stock options outstanding can be converted under the option plan. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated. No definition available.
|
| X | ||||||||||
|
- Definition
Weighted average price at which grantees can acquire the shares reserved for issuance on stock options awarded. No definition available.
|
|
Note 6 - Share Capital (Detail) - Weighted Average Option Pricing Assumptions (CAD)
|
1 Months Ended | 12 Months Ended | |||
|---|---|---|---|---|---|
|
Jun. 22, 2011
|
Dec. 31, 2012
|
Dec. 31, 2012
2007 Plan And 2011 Plan [Member]
|
Dec. 31, 2011
2007 Plan And 2011 Plan [Member]
|
Dec. 31, 2010
2007 Plan And 2011 Plan [Member]
|
|
| Dividend yield | 0.00% | 0.00% | 0.00% | ||
| Expected volatility | 120.40% | 116.26% | 116.90% | ||
| Risk-free interest rate | 1.56% | 2.51% | 2.60% | ||
| Expected average option term (years) | 10 years | 8 years 73 days | 9 years 219 days | 6 years 219 days | |
| Fair value of options granted (in Dollars per share) | 4.16 | 3.83 | 2.00 | 3.82 | |
| X | ||||||||||
|
- Definition
The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The risk-free interest rate assumption that is used in valuing an option on its own shares. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Weighted average price at which grantees can acquire the shares reserved for issuance on stock options awarded. No definition available.
|
|
Note 6 - Share Capital (Detail) - Location Of Expenses for Stock-Based Compensation (CAD)
|
12 Months Ended | ||
|---|---|---|---|
|
Dec. 31, 2012
|
Dec. 31, 2011
|
Dec. 31, 2010
|
|
| Research, development, collaborations and contracts expenses | 18,031,718 | 19,898,969 | 22,133,983 |
| General and administrative expenses | 8,135,528 | 6,312,487 | 4,780,745 |
| Total | 981,656 | 626,119 | 650,620 |
|
2007 Plan And 2011 Plan [Member]
|
|||
| Research, development, collaborations and contracts expenses | 771,869 | 494,634 | 533,508 |
| General and administrative expenses | 209,787 | 131,485 | 117,112 |
| X | ||||||||||
|
- Definition
The amount of plan compensation cost recognized during the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 6 - Share Capital (Detail) - Outstanding Options Under the Protiva Option Plan (CAD)
|
Dec. 31, 2012
|
Dec. 31, 2009
|
Dec. 31, 2009
EquivalentNumberOfCompanyCommonSharesMember
Protiva Share Options [Member]
Beginning Balance [Member]
|
Dec. 31, 2012
EquivalentNumberOfCompanyCommonSharesMember
Protiva Share Options [Member]
Exercised [Member]
|
Dec. 31, 2011
EquivalentNumberOfCompanyCommonSharesMember
Protiva Share Options [Member]
Exercised [Member]
|
Dec. 31, 2010
EquivalentNumberOfCompanyCommonSharesMember
Protiva Share Options [Member]
Exercised [Member]
|
Dec. 31, 2012
EquivalentNumberOfCompanyCommonSharesMember
Protiva Share Options [Member]
Total [Member]
|
Dec. 31, 2011
EquivalentNumberOfCompanyCommonSharesMember
Protiva Share Options [Member]
Total [Member]
|
Dec. 31, 2010
EquivalentNumberOfCompanyCommonSharesMember
Protiva Share Options [Member]
Total [Member]
|
Dec. 31, 2009
Protiva Share Options [Member]
Beginning Balance [Member]
|
Dec. 31, 2012
Protiva Share Options [Member]
Exercised [Member]
|
Dec. 31, 2011
Protiva Share Options [Member]
Exercised [Member]
|
Dec. 31, 2010
Protiva Share Options [Member]
Exercised [Member]
|
Dec. 31, 2012
Protiva Share Options [Member]
Total [Member]
|
Dec. 31, 2011
Protiva Share Options [Member]
Total [Member]
|
Dec. 31, 2010
Protiva Share Options [Member]
Total [Member]
|
Dec. 31, 2012
Exercised [Member]
|
Dec. 31, 2011
Exercised [Member]
|
Dec. 31, 2010
Exercised [Member]
|
Dec. 31, 2012
Forfeited, Cancelled or Expired [Member]
|
Dec. 31, 2011
Forfeited, Cancelled or Expired [Member]
|
Dec. 31, 2010
Forfeited, Cancelled or Expired [Member]
|
Dec. 31, 2012
Total [Member]
|
Dec. 31, 2011
Total [Member]
|
Dec. 31, 2010
Total [Member]
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Protiva Options | 1,970,145 | 865,628 | 350,457 | (10,218) | (18,366) | (574) | 321,299 | 331,517 | 349,883 | 519,073 | (15,135) | (27,202) | (850) | 475,885 | 491,020 | 518,223 | (28,417) | (1,667) | (9,548) | (62,355) | (71,547) | (47,873) | 1,648,846 | 1,413,318 | 1,083,432 |
| Equivalent number of Company common shares | 1,970,145 | 865,628 | 350,457 | (10,218) | (18,366) | (574) | 321,299 | 331,517 | 349,883 | 519,073 | (15,135) | (27,202) | (850) | 475,885 | 491,020 | 518,223 | (28,417) | (1,667) | (9,548) | (62,355) | (71,547) | (47,873) | 1,648,846 | 1,413,318 | 1,083,432 |
| Weighted average exercise price (in Dollars per share) | 10.10 | 0.30 | 0.30 | 0.30 | 0.30 | 0.30 | 0.30 | 0.30 | 2.34 | 1.50 | 3.63 | 21.27 | 27.42 | 27.38 | 4.54 | 5.32 | 7.95 |
| X | ||||||||||
|
- Definition
The number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are outstanding as of the balance sheet date, including vested options. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 7 - Government Grants and Refundable Investment Tax Credits (Detail) (CAD)
|
12 Months Ended | |
|---|---|---|
|
Dec. 31, 2011
|
Dec. 31, 2010
|
|
| Revenue from Grants | 191,194 | |
| Investment Tax Credit | 20,905 | 196,556 |
| X | ||||||||||
|
- Definition
The amount deducted from an entities' taxes, reflecting a percentage of an amount invested in certain assets spread over the useful life of those assets; includes deferred investment tax credits. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 8 - Income taxes - outstanding (Detail) (CAD)
|
1 Months Ended | 12 Months Ended | ||
|---|---|---|---|---|
|
Nov. 23, 2011
|
Dec. 31, 2012
|
Dec. 31, 2011
|
Dec. 31, 2010
|
|
| Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate | 17.50% | 26.50% | 28.50% | |
| Deferred Tax Assets, Operating Loss Carryforwards | 4,538,000 | 4,438,000 | ||
| Patent Tax Refund Percentage | 75.00% | |||
| Proceeds from Income Tax Refunds | 321,207 | 102,464 | 36,613 | |
|
Maximum [Member]
|
||||
| Proceeds from Income Tax Refunds | 8,000,000 | |||
|
Investment Tax Credit Carryforward [Member]
|
||||
| Deferred Tax Assets, Operating Loss Carryforwards, Domestic | 5,861,202 | 11,093,450 | ||
| Deferred Tax Assets, Operating Loss Carryforwards, State and Local | 1,904,908 | 5,500,315 | ||
|
Research Tax Credit Carryforward [Member]
|
||||
| Deferred Tax Assets, Operating Loss Carryforwards | 48,111,776 | 50,575,034 | ||
| Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration | 21,348,573 | 19,037,156 | ||
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates. No definition available.
|
| X | ||||||||||
|
- Definition
The domestic federal statutory tax rate applicable under enacted tax laws to the Company's pretax income from continuing operations for the period. The "statutory" tax rate is the regular tax rate if there are alternative tax systems. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of cash received during the period as refunds for the overpayment of taxes. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 8 - Income taxes - outstanding (Detail) - Income Tax Reconciliation (CAD)
|
12 Months Ended | ||
|---|---|---|---|
|
Dec. 31, 2012
|
Dec. 31, 2011
|
Dec. 31, 2010
|
|
| Computed taxes (recoveries) at Canadian federal and provincial tax rates | 7,448,281 | (2,633,285) | (3,538,412) |
| Differences due to change in enacted tax rates | 777,000 | 712,236 | |
| Difference due to change in tax rate on opening deferred taxes | 2,623,000 | 3,427,057 | |
| Permanent and other differences | 2,191,116 | 143,992 | 1,409,918 |
| Change in valuation allowance | (2,503,000) | (1,650,000) | 2,880,000 |
| Utilization of investment tax credits | (10,536,397) | ||
| Utilization of non-capital loss carryforwards | (751,506) | ||
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
The portion of the difference between total income tax expense or benefit as reported in the Income Statement and the expected income tax expense or benefit computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations attributable to changes in the valuation allowance for deferred tax assets in the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The portion of the difference between total income tax expense or benefit as reported in the Income Statement and the expected income tax expense or benefit computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations, that is attributable to changes in the income tax rates under enacted tax laws in the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The portion of the difference between total income tax expense or benefit as reported in the Income Statement for the period and the expected income tax expense or benefit computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations attributable to other deductions received under enacted tax laws not otherwise listed in the existing taxonomy. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The portion of the difference, between total income tax expense or benefit as reported in the Income Statement for the year/accounting period and the expected income tax expense or benefit computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations, that is attributable to all other items not otherwise listed in the existing taxonomy. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The portion of the difference between total income tax expense or benefit as reported in the Income Statement and the expected income tax expense or benefit computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations attributable to investment tax credits generated or utilized under enacted tax laws during the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 8 - Income taxes - outstanding (Detail) - Deferred Tax Assets (CAD)
|
Dec. 31, 2012
|
Dec. 31, 2011
|
|---|---|---|
| Non-capital loss carryforwards | 4,538,000 | 4,438,000 |
| Research and development deductions | 8,540,000 | 9,295,000 |
| Book amortization in excess of tax | 1,925,000 | 2,779,000 |
| Share issue costs | (26,000) | 45,000 |
| Warrant liability | 724,000 | 65,000 |
| Revenue recognized for tax purposes in excess of revenue recognized for accounting purposes | 1,125,000 | |
| Tax value in excess of accounting value in lease inducements | 8,000 | 49,000 |
| Accounting value in excess of tax value in intangible assets | 371,000 | 49,000 |
| Provincial investment tax credits | 303,000 | 973,000 |
| Total deferred tax assets | 16,383,000 | 18,818,000 |
| Valuation allowance | (16,383,000) | (18,818,000) |
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
The noncurrent portion of the reserve for accumulated deferred investment tax credits as of the balance sheet date. This is the remaining investment credit, which will reduce the cost of services collected from ratepayers by a ratable portion over the investment's regulatory life. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 9 - Contingencies and commitments (Detail)
|
1 Months Ended | 2 Months Ended | 12 Months Ended | 12 Months Ended | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Mar. 31, 2004
CAD
|
Dec. 31, 2012
USD ($)
|
Dec. 31, 2012
CAD
|
Dec. 31, 2013
USD ($)
|
Dec. 31, 2012
USD ($)
|
Dec. 31, 2012
CAD
|
Dec. 31, 2011
USD ($)
|
Dec. 31, 2011
CAD
|
Dec. 31, 2010
CAD
|
Jul. 14, 2010
USD ($)
|
May 11, 2009
USD ($)
|
Dec. 31, 2012
Up-front Payment Arrangement [Member]
USD ($)
|
Dec. 31, 2012
Up-front Payment Arrangement [Member]
CAD
|
Dec. 31, 2012
Maximum [Member]
USD ($)
|
Dec. 31, 2012
Research and Development [Member]
USD ($)
|
Dec. 31, 2012
Research and Development [Member]
CAD
|
Mar. 25, 2008
Protiva [Member]
USD ($)
|
Mar. 25, 2008
Merck [Member]
USD ($)
|
|
| Operating Leases, Rent Expense, Net | 936,760 | 933,528 | 931,606 | |||||||||||||||
| Operating Leases, Income Statement, Sublease Revenue | 171,923 | 194,281 | 194,281 | |||||||||||||||
| Percent of Costs Funded by TPC | 27.00% | |||||||||||||||||
| Maximum Contribution for Product | 9,329,912 | |||||||||||||||||
| Cumulative Contribution for Product | 3,701,571 | |||||||||||||||||
| Dividends Payable (in Dollars) | 12,000,000 | |||||||||||||||||
| Potential Contract Funding Amount (in Dollars) | 34,700,000 | 8,800,000 | 12,000,000 | |||||||||||||||
| License Costs | 300,000 | 298,080 | 8,500,000 | 1,492,350 | 100,000 | 97,940 | 1,300,000 | 450,000 | 447,780 | |||||||||
| License Costs (in Dollars) | 300,000 | 298,080 | 8,500,000 | 1,492,350 | 100,000 | 97,940 | 1,300,000 | 450,000 | 447,780 | |||||||||
| Milestone Payment (in Dollars) | 3,250,000 | 12,700,000 | ||||||||||||||||
| Upfront Fee | $ 200,000 | $ 300,000 | 298,098 | |||||||||||||||
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Costs incurred and are directly related to generating license revenue. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of revenue recognized for the period under subleasing arrangements. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 9 - Contingencies and commitments (Detail) - Minimum Commitment for Rent and Estimated Operating Costs (CAD)
|
Dec. 31, 2012
|
|---|---|
| Year ended December 31, 2013 | 1,285,000 |
| Year ended December 31, 2014 | 750,000 |
| 2,035,000 |
| X | ||||||||||
|
- Definition
Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of required minimum rental payments maturing in the next fiscal year following the latest fiscal year for operating leases having an initial or remaining non-cancelable letter-terms in excess of one year. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of required minimum rental payments maturing in the second fiscal year following the latest fiscal year for operating leases having an initial or remaining non-cancelable letter-terms in excess of one year. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 10 - Concentrations of business risk (Detail)
|
12 Months Ended | ||||||
|---|---|---|---|---|---|---|---|
|
Dec. 31, 2012
CAD
|
Dec. 31, 2011
CAD
|
Dec. 31, 2012
US Government [Member]
Accounts Receivable [Member]
|
Dec. 31, 2011
US Government [Member]
Accounts Receivable [Member]
|
Dec. 31, 2012
US Government [Member]
CAD
|
Dec. 31, 2011
US Government [Member]
CAD
|
Nov. 30, 2012
Foreign Exchange Forward [Member]
USD ($)
|
|
| Accounts Receivable, Net | 1,069,437 | 880,693 | 947,802 | 747,720 | |||
| Concentration Risk, Percentage | 89.00% | 85.00% | |||||
| Forward Exchange Contract (in Dollars) | $ 45,000,000 | ||||||
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
For an unclassified balance sheet, the amount due from customers or clients for goods or services that have been delivered or sold in the normal course of business, reduced to their estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 10 - Concentrations of business risk (Detail) - Net Liquidity of the Company
|
12 Months Ended | |||||
|---|---|---|---|---|---|---|
|
Dec. 31, 2011
CAD
|
Dec. 31, 2012
USD ($)
|
Dec. 31, 2012
CAD
|
Dec. 31, 2011
USD ($)
|
Dec. 21, 2011
USD ($)
|
Dec. 21, 2011
CAD
|
|
| Cash, cash equivalents and short term investments | 9,184,134 | 46,785,518 | ||||
| Debt facility available (US$3,000,000) | 3,051,000 | 3,000,000 | 3,000,000 | 3,000,000 | 3,051,000 | |
| Less: Debt facility repayments in first 12 months | (1,135,000) | |||||
| Less: Accounts payable and accrued liabilities | (3,972,551) | (3,776,287) | ||||
| 7,127,583 | 43,009,231 | |||||
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The cash outflow to pay off an obligation from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 10 - Concentrations of business risk (Detail) - Net Liquidity of the Company (Parentheticals)
|
Dec. 31, 2012
USD ($)
|
Dec. 31, 2011
USD ($)
|
Dec. 31, 2011
CAD
|
Dec. 21, 2011
USD ($)
|
Dec. 21, 2011
CAD
|
|---|---|---|---|---|---|
| Debt facility available in US dolalrs | $ 3,000,000 | $ 3,000,000 | 3,051,000 | $ 3,000,000 | 3,051,000 |
| X | ||||||||||
|
- Definition
Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 10 - Concentrations of business risk (Detail) - Foreign Currency Exposure (CAD)
|
Dec. 31, 2012
|
Dec. 31, 2011
|
Dec. 31, 2010
|
Dec. 31, 2009
|
|---|---|---|---|---|
| Cash and cash equivalents | 46,785,518 | 9,184,134 | 12,346,010 | 24,397,740 |
| Accounts receivable | 1,069,437 | 880,693 | ||
| Accrued revenue | 2,361,836 | 185,356 | ||
| Accounts payable and accrued liabilities | 3,776,287 | 3,972,551 | ||
|
Foreign Currency Exposure [Member]
|
||||
| Cash and cash equivalents | 149,058 | 1,259,029 | ||
| Accounts receivable | 1,025,306 | 780,176 | ||
| Accrued revenue | 2,361,836 | 185,356 | ||
| Accounts payable and accrued liabilities | (2,969,454) | (2,365,191) | ||
|
Total [Member]
|
||||
| 566,746 | (325,986) |
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
For an unclassified balance sheet, the amount due from customers or clients for goods or services that have been delivered or sold in the normal course of business, reduced to their estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount due for services rendered or products shipped, but not yet billed, recognized in conformity with revenue recognition criteria. This element is distinct from unbilled contracts receivables because this is based on noncontract transactions. No definition available.
|
|
Note 11 - Supplementary information (Detail) - Accounts Payable and Accrued Liabilities (CAD)
|
Dec. 31, 2012
|
Dec. 31, 2011
|
|---|---|---|
| Trade accounts payable | 801,701 | 1,284,737 |
| Accrued Liabilities, Other | 342,193 | 555,934 |
| 3,776,287 | 3,972,551 | |
|
Research and Development Accruals [Member]
|
||
| Accrued Liabilities, Other | 308,917 | 228,942 |
|
License Fee Accruals [Member]
|
||
| Accrued Liabilities, Other | 1,641,585 | |
|
Professional Fee Accruals [Member]
|
||
| Accrued Liabilities, Other | 599,058 | 1,669,838 |
|
Restructuring Cost Accruals [Member]
|
||
| Accrued Liabilities, Other | 34,999 | 36,134 |
|
Deferred Lease Inducements [Member]
|
||
| Accrued Liabilities, Other | 47,834 | 196,966 |
| X | ||||||||||
|
- Definition
Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Carrying value as of the balance sheet date of obligations incurred and payable, which are not elsewhere specified in the taxonomy. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|